WO2003062369A2 - Expansion of renewable stem cell populations - Google Patents
Expansion of renewable stem cell populations Download PDFInfo
- Publication number
- WO2003062369A2 WO2003062369A2 PCT/IL2003/000064 IL0300064W WO03062369A2 WO 2003062369 A2 WO2003062369 A2 WO 2003062369A2 IL 0300064 W IL0300064 W IL 0300064W WO 03062369 A2 WO03062369 A2 WO 03062369A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- tetrahydro
- butyl
- naphthyl
- stem cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/14—Bags
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
Definitions
- the present invention relates to methods of expansion of renewable stem cells, to expanded populations of renewable stem cells and to their uses.
- the present invention relates to methods of reducing the expression and/or activity of CD38.
- ex-vivo and/or in-vivo stem cell expansion is achieved according to the present invention by downregulation of retinoic acid receptor (RAR), retinoid X receptor (RXR), and/or Vitamin D receptor (NDR) signaling, either at the protein level via RAR, RXR and/or NDR antagonists or at the expression level via genetic engineering techniques, such as small interfering R ⁇ A (siR ⁇ A) techniques.
- RAR retinoic acid receptor
- RXR retinoid X receptor
- NDR Vitamin D receptor
- ex-vivo and/or in-vivo stem cell expansion is achieved according to the present invention by downregulation of CD38 either at the protein level via CD38 inhibitors, such as, for example, nicotinamide, or at the expression level via genetic engineering techniques, such as small interfering R ⁇ A (siR ⁇ A) techniques.
- CD38 inhibitors such as, for example, nicotinamide
- genetic engineering techniques such as small interfering R ⁇ A (siR ⁇ A) techniques.
- the present invention further relates to therapeutic applications in which these methods and/or the expanded stem cells populations obtained thereby are utilized.
- An increasing need for ex-vivo cultures of hematopoietic and non- hematopoietic stem cells has arisen, in particular for purposes such as stem cell expansion and retroviral-mediated gene transduction.
- stem cells have been achieved either by growing the stem cells over a feeder layer of fibroblast cells, or by growing the cells in the presence of the early acting cytokines thrombopoietin (TPO), interleukin-6 (IL-6), an FLT-3 ligand and stem cell factor (SCF) (Madlambayan GJ et al (2001) J Hematother Stem Cell Res 10: 481, Punzel M et al (1999) Leukemia 13: 92, and Lange W et al (1996) Leukemia 10: 943).
- TPO thrombopoietin
- IL-6 interleukin-6
- SCF stem cell factor
- stem cells While expanding stem cells over a feeder layer results in vast, substantially endless cell expansion, expanding stem cells without a feeder layer, in the presence of the early acting cytokines, results in an elevated degree of differentiation (see controls described in the Examples section and Leslie NR et al (Blood (1998) 92: 4798), Petzer AL et al (1996) J Exp Med Jun 183: 2551, Kawa Y et al (2000) Pigment Cell Res 8: 73). In any case, using present day technology, stem cells cannot be expanded unless first substantially enriched or isolated to homogeneity.
- CD38 is a member of an emerging family of cytosolic and membrane-bound enzymes whose substrate is nicotinamide adenine dinucleotide (NAD), a coenzyme ubiquitously distributed in nature. In human, CD38 is a 45 kDa type II trans-membrane glycoprotein.
- NAD nicotinamide adenine dinucleotide
- CD38 is a multifunctional enzyme that exerts both NAD + glycohydrolase activity and ADP-ribosyl cyclase activity and is thus able to produce nicotinamide, ADP-ribose (ADPR), cyclic-ADPR (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) from its substrates (Howard et al., 1993 Science 252: 1056-1059; Lee et al., 1999 Biol. Chem. 380;785-793).
- ADPR ADP-ribose
- cADPR cyclic-ADPR
- NAADP nicotinic acid adenine dinucleotide phosphate
- the soluble domain of human CD38 catalyzes the conversion of NAD + to cyclic ADP-ribose and to ADP-ribose via a common covalent intermediate (Sauve, A. A., Deng, H. T., Angelletti, R. H., and Schramm, N. L.
- CD38 is not characterized only by multi enzymatic activity but is further able to mobilize calcium, to transduce signals and to adhere to hyaluronan and to other ligands.
- CD38 a surface receptor, an enzyme, an adhesion molecule and not a simple marker.
- CD38 is widely expressed in both hematopoietic and non hematopoietically-derived cells. Homologues of CD38 have also been found to be expressed in mammalian stromal cells (Bst-1) and in cells isolated from the invertebrate Aplysia californica (Prasad GS, 1996, nature Structural Biol 3:957-964).
- cADPR and ⁇ AADP Two of the metabolites produced by CD38, cADPR and ⁇ AADP, have been shown to induce the release of intracellular calcium in cells isolated from tissues of plants, invertebrates and mammals, suggesting that these metabolites may be global regulators of calcium responses (Lee et al., 1999 Biol. Chem. 380;785-793). Both cADPR and ⁇ AADP are known to induce calcium release from calcium stores that are distinct from those controlled by lp receptors (Clapper, D L et al., 1987, J. Biological Chem. 262:9561-9568).
- CD38 being the best-characterized mammalian ADP-ribosyl cyclase, is postulated to be an important source of cyclic ADP-ribose in vivo.
- ⁇ ucleoplasmic calcium ions influence highly important nuclear functions such as gene transcription, apoptosis, D ⁇ A repair, topoisomerase activation and polymerase unfolding.
- inositol trisphosphate receptors and ryanodine receptors which are types of Ca +2 channel, are present in the nuclear membrane, their role in the homeostasis of nuclear Ca +2 is still unclear. It was found that CD38/ADP-ribosyl cyclase has its catalytic site within the nucleoplasm and hence it catalyses the intranuclear cyclization of NAD + , to produce nucleoplasmic cADPR. The latter activates ryanodine receptors of the
- cADPR is likely to regulate calcium responses in tissues such as muscle and pancreas, where ryanodine receptors are expressed (Day et al., 2000 Parasitol 120:417-422; Silva et al., 1998, Biochem. Pharmacol 56:997-1003).
- Differentiation in the hematopoietic system involves, among other changes, altered expression of surface antigens (Sieff C, Bicknell D, Caine G, Robinson J, Lam G, Greaves MF (1982) Changes in cell surface antigen expression during hematopoietic differentiation. Blood 60:703).
- most of the hematopoietic pluripotent stem cells and the lineage committed progenitor cells are CD34+.
- the majority of cells are CD34+CD38+, with a minority of cells ( ⁇ 10 %) being CD34+CD38-.
- the CD34+CD38- phenotype appears to identify the most immature hematopoietic cells, which are capable of self-renewal and multilineage differentiation.
- the CD34+CD38- cell fraction contains more long-term culture initiating cells (LTC-IC) pre-CFU and exhibits longer maintenance of their phenotype and delayed proliferative response to cytokines as compared with CD34+CD38+ cells.
- LTC-IC long-term culture initiating cells
- CD34+CD38- can give rise to lymphoid and myeloid cells in vitro and have an enhanced capacity to repopulate SCID mice (Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 94:5320).
- CD34+CD38- cells infused correlated positively with the speed of hematopoietic recovery.
- CD34+CD38- cells have been shown to have detectable levels of telomerase.
- CD38 expression was achieved by using morpholino antisense oligonucleotides targeting its mRNA, which produced a corresponding inhibition of differentiation as well (Munshi CB, Graeff R, Lee HC, J Biol Chem 2002 Dec 20;277(51):49453-8).
- the present inventors have envisioned that by modulating the expression and/or the activity of CD38, the expansion and differentiation of stem cells could be controlled.
- Nicotinamide (NA) is a water-soluble derivative of vitamin B, whose physiological active forms are nicotinamide adenine dinucleotide (NAD+ NADH) and nicotinamide adenine dinucleotide phosphate (NADP+/NADPH).
- the physiological active forms of NA serve as coenzyme in a variety of important metabolic reactions. Nicotinamide is further known to inhibit the enzymatic activity of CD38, to thereby affect the cADPR signal transduction pathway, a feature which is demonstrated, for example, in the studies described hereinabove (see, for example, Munshi CB, Graeff R, Lee HC, JBiol Chem 2002 Dec 20;277(51):49453-8).
- nicotinamide as well as other agents known to inhibit the enzymatic activity of CD38, can be utilized for expanding stem cell populations while inhibiting the differentiation of the stem cells. It was further hypothesized that other small molecules, which are capable of interfering, directly or indirectly, with the expression of CD38 can be similarly used.
- Retinoic acid the natural acidic derivative of Nitamin A (retinol) is an important regulator of embryonic development and it also influences the growth and differentiation of a wide variety of adult cell types.
- the biological effects of RA are generally mediated through their interaction with specific ligand-activated nuclear transcription factors, their cognate RA receptors (RARs).
- RARs RA receptors
- Receptors of the retinoic acid family comprise RARs, RXRs, Nitamin D receptors (NDRs), thyroid hormone receptors (THRs) and others. When activated by specific ligands these receptors behave as transcription factors, controlling gene expression during embryonic and adult development.
- RAR and RXR families of receptors uniquely exhibit modular structures harboring distinct D ⁇ A-binding and ligand-binding domains. These receptors probably mediate their biological effects by binding to regulatory elements (e.g., retinoic acid response elements, or RAREs) as RAR-RXR heterodimers that are present in the promoters of their specific target genes (1, 2, 3).
- regulatory elements e.g., retinoic acid response elements, or RAREs
- Retinoid receptors thus behave as ligand-dependent transcriptional regulators, repressing transcription in the absence of ligand and activating transcription in its presence. These divergent effects on transcription are mediated through the recruitment of co-regulators: un-liganded receptors bind corepressors (NCoR and SMRT) that are found within a complex exhibiting histone deacetylase (HDAC) activity, whereas liganded receptors recruit co-activators with histone acetylase activity (HATs). Chromatin remodeling may also be required, suggesting a hierarchy of promoter structure modifications in RA target genes carried out by multiple co-regulatory complexes.
- NoR and SMRT histone deacetylase
- HATs histone acetylase activity
- the first retinoic acid receptor identified, designated RAR-alpha modulates transcription of specific target genes in a manner which is ligand-dependent, as subsequently shown for many of the members of the steroid/thyroid hormone intracellular receptor superfamily.
- Retinoic acid receptor-mediated changes in gene expression result in characteristic alterations in cellular phenotype, affecting multiple tissues.
- Additional RAR-alpha related genes have been identified, designated RAR-beta and RAR-gamma, and exhibit a high level of homology to RAR-alpha and each other (4, 5).
- the ligand-binding region of the three RAR subtype receptors has a primary amino acid sequence divergence of less than 15 %.
- additional members of the steroid/thyroid receptor superfamily responsive to retinoic acid have been identified (6), and have been designated as the retinoid X receptor (RXR) family.
- RXR retinoid X receptor
- the RXRs are also known to comprise at least three subtypes or isoforms, namely RXR-alpha, RXR-beta, and RXR-gamma, with corresponding unique patterns of expression
- both the RARs and RXRs bind the ligand all-trans-retinoic acid in vivo, the receptors differ in several important aspects.
- RXRs significantly differ in their primary structure, especially regarding their ligand binding domains (e.g., alpha domains exhibit a mere 27 % shared amino acid identity). These structural differences manifest in their differing relative degrees of responsiveness to various Nitamin A metabolites and synthetic retinoids. Additionally, tissue distribution patterns are distinctly different for
- RARs and RXRs exhibit different target gene specificity.
- Nitamin D is an additional potent activator of one of the receptors belonging to the retinoid receptor superfamily.
- the nuclear hormone 1 alpha, 25-dihydroxyvitamin D (3) (1 alpha, 25 (OH) (2) D (3)) binds its cognate receptor (NDR) and acts as a transcription factor when in combined contact with the retinoid X receptor (RXR), coactivator proteins, and specific D ⁇ A binding sites (NDREs).
- Ligand-mediated conformational changes of the NDR comprise the molecular switch controlling nuclear 1 alpha, 25 (OH) (2) D (3), signaling events.
- NDR antagonists reveal the extremely control and regulation of the pleiotropic 1 alpha, 25 (OH) (2) D (3) endocrine system, with consequences in maintenance of calcium homeostasis, bone mineralization and other cellular functions.
- Antagonists to NitD were shown to act via the same mechanism: they selectively stabilize an antagonistic conformation of the ligand-binding domain of the VDR within NDR-RXR-NDRE complexes, inhibiting the interaction of the VDR with coactivator proteins and induction of transactivation.
- cells treated with NitD antagonists contain VDR-RXR heterodimers in different conformations as compared to cells stimulated with NitD agonists (16).
- Retinoic acid and NitD can cooperatively stimulate transcriptional events involving a common D ⁇ A binding site or hormone response element (HRE).
- HRE hormone response element
- NDR/RXR heterodimers have been found to bind without defined polarity and in a transcriptionally unproductive manner to certain RA response elements, and under these circumstances Nitamin D inhibits the response to RA.
- competition for binding to D ⁇ A may contribute to this inhibitory response
- titration of common coactivators by NDR also appears to be involved in this trans-repression. Therefore, the regulation of the transcriptional response to RA and VitD is dependent upon a complex combinatory pattern of interaction among the different receptors, co-activators (17) and their binding to the appropriate D ⁇ A binding sites.
- retinoid receptors such as RAR and RXR play important roles in regulating the growth and differentiation of a variety of cell-types, as well (18).
- RAR agonists such as all-trans-retinoic acid (ATRA) are predominantly known for their effects in inducing cell-differentiation, as seen in experiments utilizing malignant cancer cells and embryonic stem cells (19), where potent induction of terminal differentiation was evident.
- ATRA all-trans-retinoic acid
- Cell differentiation is not an exclusive result, however, as RA has been shown to exhibit different effects on cultured hematopoietic cells, depending on their maturational state (20).
- retinoids accelerated the growth and differentiation of granulocyte progenitors in cytokine-stimulated cultures of purified CD34 + cells
- use of stem cells produced an opposite effect (42).
- Retinoid treatment has also been shown to inhibit differentiation of pre-adipose cells (43).
- the RAR antagonist AG ⁇ 193109 exerted a positive effect on the differentiation of hematopoietic stem cells (41)
- the RAR agonist 4-[4-(4-ethylphenyl)dimethyl-chromen-yl]ethynyl ⁇ -benzoic acid] functions in an opposing manner.
- RAR antagonists have been shown to prevent granulocytic differentiation in experiments utilizing the promyelocytic cell line, HL-60 (41).
- retinoid-def ⁇ cient tissues acquire a pre-malignant phenotype, and a concomitant loss of differentiation (29, 30).
- Malignant cell lines derived from various carcinomas exhibit diminished expression of retinoic acid receptor mRNA, implying that the loss of expression may be an important event in tumorogenesis (33, 34, 35, 36, 37).
- disruption of retinoic acid receptor activity as evidenced in knock-out mouse models disrupted for the RAR gene, display an in vitro block to granulocytic differentiation (38, 39).
- hematopoietic stem and early progenitor cells are characterized by their surface expression of the surface antigen marker known as CD34 + , and exclusion of expression of the surface lineage antigen markers, Lin " .
- CD34 + the surface antigen marker
- Lin " the surface lineage antigen markers
- Some pathological and medically induced conditions are characterized by a low number of in-vivo self or transplanted renewable stem cells, in which conditions, it will be advantageous to have an agent which can induce stem cell expansion in-vivo.
- the present invention discloses the use of various molecules for interfering with CD38 expression and/or activity, thereby inducing ex-vivo and/or in-vivo expansion of stem cell populations, resulting, when applied, for example, to hematopoietic stem cells, in large numbers of undifferentiated CD34 + Lin (CD33, CD14, CDI 5, CD4, etc.), as well as CD34 + /CD38 " cells, especially CD34 + dim /Lin " cells.
- This novel and versatile technology may be used for ex-vivo and in-vivo expansion of stem cells, of hematopoietic and other origins, maintaining their self-renewal potential for any in-vivo or ex-vivo application which requires large numbers of stem cell populations.
- nicotinamide a well-known CD38 inhibitor
- nicotinamide a well-known CD38 inhibitor
- a series of chemical agents, retinoic acid receptor antagonists of the RAR and RXR superfamilies, and Vitamin D receptor antagonists which have been shown to affect CD38 expression, also repress the process of differentiation of stem cells and stimulates and prolongs, for up to 16-18 weeks, the phase of active cell proliferation and expansion ex-vivo.
- an assay of determining whether a retinoic acid receptor antagonist, a retinoid X receptor antagonist or a Vitamin D receptor antagonist is an effective cell expansion agent comprising culturing a population of stem cells or cells of a substantially non-differentiated cell line, in the presence of the retinoic acid receptor antagonist, the retinoid X receptor antagonist or the Vitamin D receptor antagonist and monitoring expansion of the cells, wherein if increased expansion and decreased differentiation occurs, as compared to non-treated cells, the retinoic acid receptor antagonist, the retinoid X receptor antagonist or the Vitamin D receptor antagonist is an effective cell expansion agent.
- culturing the population of stem cells or cells of a substantially non-differentiated cell line is performed in a presence of an effective amount of a cytokine, preferably, an early acting cytokine.
- a cytokine preferably, an early acting cytokine.
- This assay can be used, by one ordinarily skilled in the art, to determine which of the antagonists listed below is most efficient for the purpose of implementing the various methods, preparations and articles-of-mamifacture of the present invention which are further described hereinafter.
- the method comprises providing the stem cells with ex-vivo culture conditions for ex-vivo cell proliferation and, at the same time, for reducing the activity and/or expression of CD38, thereby expanding the population of stem cells while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- the method comprises providing the stem cells with ex-vivo culture conditions for ex-vivo cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding the population of stem cells while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- the method comprises providing the stem cells with ex-vivo culture conditions for ex-vivo cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor, retinoid-X receptor and/or Vitamin D receptor, thereby expanding the population of stem cells while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- the method comprises providing the stem cells with ex-vivo culture conditions for ex-vivo cell proliferation and, at the same time, with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding the population of stem cells while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- the method comprises administering to a subject in need thereof a therapeutically effective amount of an agent, the agent serves for reducing an expression and/or activity of CD38.
- the method comprises administering to a subject in need thereof a therapeutically effective amount of an agent, the agent serves for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D.
- the method comprises administering to a subject in need thereof a therapeutically effective amount of an agent, the agent serves for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor, retinoid-X receptor and/or Vitamin D receptor.
- the method comprises administering to a subject in need thereof a therapeutically effective amount of an agent selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite.
- an agent selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite.
- the method comprises obtaining adult or neonatal umbilical cord whole white blood cells or whole bone marrow cells sample and providing the cells in the sample with ex-vivo culture conditions for stem cells ex-vivo cell proliferation and, at the same time, for reducing the expression and/or activity of CD38, thereby expanding a population of a renewable stem cells in the sample.
- the method comprises obtaining adult or neonatal umbilical cord whole white blood cells or whole bone marrow cells sample and providing the cells in the sample with ex-vivo culture conditions for stem cells ex-vivo cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding a population of a renewable stem cells in the sample.
- the method comprises obtaining adult or neonatal umbilical cord whole white blood cells or whole bone marrow cells sample and providing the cells in the sample with ex-vivo culture conditions for stem cells ex-vivo cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor, thereby expanding a population of a renewable stem cells in the sample.
- the method comprises obtaining adult or neonatal umbilical cord whole white blood cells or whole bone marrow cells sample and providing the cells in the sample with ex-vivo culture conditions for stem cells ex-vivo cell proliferation and, at the same time, with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding a population of a renewable stem cells in the sample.
- the method comprises (a) obtaining stem cells to be genetically modified; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing the expression and/or activity of CD38, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) genetically modifying the stem cells with the exogene.
- the method comprises (a) obtaining stem cells to be genetically modified; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) genetically modifying the stem cells with the exogene.
- the method comprises (a) obtaining stem cells to be genetically modified; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor and/or the retinoid X receptor and/or the Vitamin D receptor, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) genetically modifying the stem cells with the exogene.
- the method comprises (a) obtaining stem cells to be genetically modified; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) genetically modifying the stem cells with the exogene.
- genetically modifying the cells is effected by a vector, which comprises the exogene, which vector is, for example, a viral vector or a nucleic acid vector.
- a fransplantable hematopoietic cell preparation of the present invention comprises an expanded population of hematopoietic stem cells propagated ex-vivo in the presence of an effective amount of an agent, the agent reducing an expression and/or activity of CD38, while at the same time, substantially inhibiting differentiation of the stem cells; and a pharmaceutically acceptable carrier.
- a transplantable hematopoietic cell preparation of the present invention comprise an expanded population of hematopoietic stem cells propagated ex-vivo in the presence of an effective amount of an agent, the agent reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, while at the same time, substantially inhibiting differentiation of the stem cells; and a pharmaceutically acceptable carrier.
- a transplantable hematopoietic cell preparation of the present invention comprises an expanded population of hematopoietic stem cells propagated ex-vivo in the presence of an effective amount of an agent, the agent reducing a capacity of the stem cells in responding to retinoic acid receptor, retinoid X receptor and/or Vitamin D receptor signaling, while at the same time, substantially inhibiting differentiation of the stem cells; and a pharmaceutically acceptable carrier.
- a transplantable hematopoietic cell preparation of the present invention comprises an expanded population of hematopoietic stem cells propagated ex-vivo in the presence of an effective amount of an agent selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite, while at the same time, substantially inhibiting differentiation of the stem cells; and a pharmaceutically acceptable carrier.
- an ex-vivo expanded population of hematopoietic stem cells comprising a plurality of cells characterized by 3-20 % of the cells being reselectable for CD34 + cells, of which at least 40 % of cells are CD34 + dim , wherein, in the reselectable CD34 + cells, a majority of cells which are Lin " are also CD34 + dim cells.
- the hematopoietic stem cells are derived from a source selected from the group consisting of bone marrow, peripheral blood and neonatal umbilical cord blood.
- the population of cells has a single genetic background.
- the ex-vivo expanded population of hematopoietic stem cells comprises at least N cells derived from a single donor, wherein N equals the average number of CD34 + cells derived from one sample of neonatal umbilical cord blood, bone marrow, or peripheral blood multiplied by 1 ,000.
- Cell surface expression of the CD34 and/or Lin markers can be determined, for example, via FACS analysis or immunohistological staining techniques.
- a self renewal potential of the stem cells can be determined by long term colony formation (LTC-CFUc) or by in vivo engraftment in a SCID-Hu mouse model.
- a method of preserving stem cells comprising handling the stem cell in at least one of the steps selected from the group consisting of harvest, isolation and storage, in a presence of an effective amount of a retinoic acid receptor antagonist, a retinoid X receptor antagonist and/or a Vitamin D receptor antagonist.
- the method comprises handling the stem cell in at least one of the steps selected from the group consisting of harvest, isolation and storage, in a presence of an effective amount of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite.
- a cells collection/culturing bag supplemented with an effective amount of a retinoic acid receptor antagonist, a retinoid X receptor antagonist and/or a Vitamin D receptor antagonist, which substantially inhibits cell differentiation, or with an effective amount of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite, which substantially inhibits cell differentiation as well; and a cells separation and/or washing buffer supplemented with an effective amount of a retinoic acid receptor antagonist, a retinoid X receptor antagonist and/or a Vitamin D receptor antagonist, which substantially inhibits cell differentiation, or with an effective amount of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nico
- the method comprises (a) obtaining hematopoietic stem cells to be transplanted from a donor; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing an expression and/or activity of CD38, thereby expanding the population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) transplanting or implanting the stem cells to a recipient.
- the method comprises (a) obtaining hematopoietic stem cells to be transplanted from a donor; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding the population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) transplanting or implanting the stem cells to a recipient.
- the method comprises (a) obtaining hematopoietic stem cells to be transplanted from a donor; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor, thereby expanding the population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) transplanting or implanting the stem cells to a recipient.
- the method comprises (a) obtaining hematopoietic stem cells to be transplanted from a donor; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding the population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) transplanting or implanting the stem cells to a recipient.
- the donor and the recipient can be a single individual or different individuals, for example, allogeneic individuals.
- the method comprises (a) obtaining hematopoietic stem cells from a recipient; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing an expression and/or activity of CD38, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (c) transplanting the stem cells to the recipient.
- the method comprises (a) obtaining hematopoietic stem cells from a recipient; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (c) transplanting the stem cells to the recipient.
- the method comprises (a) obtaining hematopoietic stem cells from a recipient; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor and/or the retinoid X receptor and/or the Vitamin D receptor, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (c) transplanting the stem cells to the recipient.
- the method comprises (a) obtaining hematopoietic stem cells from a recipient; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (c) transplanting the stem cells to the recipient.
- a method of mobilization of bone marrow stem cells into the peripheral blood of a donor for harvesting the cells comprises (a) administering an effective amount of an agent to the donor for reducing an expression and/or activity of CD38, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (b) harvesting the cells by leukophoresis.
- the method comprises (a) administering an effective amount of an agent to the donor for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (b) harvesting the cells by leukophoresis.
- the method comprises (a) administering an effective amount of an agent to the donor for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor and/or the retinoid X receptor and/or the Vitamin D receptor, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (b) harvesting the cells by leukophoresis.
- the method comprises (a) administering to the donor an effective amount of an selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (b) harvesting the cells by leukophoresis.
- the methods of mobilization of stem cells further comprising administering to the donor at least one cytokine, preferably at least one early cytokine.
- reducing the expression and/or activity of CD38 is effected by an agent that downregulates CD38 expression.
- the agent that downregulates CD38 expression is selected from the group consisting of a retinoic acid receptor antagonist, a retinoid X receptor antagonist and a Vitamin D receptor antagonist.
- this agent is an antagonist for reducing a capacity of the stem cells in responding to retinoic acid, retinoid and/or Vitamin D.
- the agent that downregulates CD38 expression is a polynucleotide.
- the agent that downregulates CD38 expression the polynucleotide encodes an anti CD38, an anti retinoic acid receptor, an anti retinoid X receptor or an anti Vitamin D receptor antibody or intracellular antibody.
- the agent that downregulates CD38 expression the polynucleotide is a small interfering polynucleotide molecule directed to cause intracellular CD38, retinoic acid receptor, retinoid X receptor or Vitamin D receptor mRNA degradation.
- the agent that downregulates CD38 expression the small interfering polynucleotide molecule is selected from the group consisting of an
- RNAi molecule an anti-sense molecule, a rybozyme molecule and a DNAzyme molecule.
- reducing the expression and/or activity of CD38 is effected by an agent that inhibits CD38 activity.
- the agent can be, for example, nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite.
- the nicotinamide analog is preferably selected from the group consisting of benzamide, nicotinethioamide, nicotinic acid and ⁇ -amino-3-indolepropionic acid.
- providing the stem cells with the conditions for ex-vivo cell proliferation comprises providing the cells with nutrients and with cytokines.
- the cytokines are early acting cytokines.
- the early acting cytokines are selected from the group comprising stem cell factor, FLT3 ligand, interleukin- 1 , interleukin-2, interleukin-3, interleukin-6, interleukin- 10, interleukin-12, tumor necrosis factor- ⁇ and thrombopoietin.
- the cytokines are late acting cytokines.
- the late acting cytokines are selected from the group comprising granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, erythropoietin, FGF, EGF, NGF, VEGF, LIF, Hepatocyte growth factor and macrophage colony stimulating factor.
- the stem cells are selected from the group consisting of embryonic stem cells and adult stem cells.
- the stem cells are hematopoietic stem cells.
- the stem cells are derived from a source selected from the group consisting of bone marrow, peripheral blood and neonatal umbilical cord blood.
- the stem cells that undergo expansion are mixed (e.g., not separated from, not enriched) with committed cells.
- the stem cells are enriched for hematopoietic CD34 + cells.
- the hematopoietic cells are characterized by an absence, or significantly diminished expression of cell surface antigens CD38, CD3, CD61, CD 19, CD33, CD14, CDI 5 or CD4.
- reducing the capacity of the stem cells in responding to signaling pathways is reversible, e.g., inherently reversible.
- reducing the capacity of the stem cells in responding to the above antagonists and/or signaling pathways of the above receptors is by ex-vivo culturing the stem cells in a presence of an effective amount of at least one retinoic acid receptor antagonist, at least one retinoid X receptor antagonist and/or at least one Vitamin D receptor antagonist, preferably, for a time period of 0.1-50 %, preferably, 0.1-25 %, more preferably, 0.1-15 %, of an entire ex-vivo culturing period of the stem cells.
- the retinoic acid receptor antagonist is selected from the group consisting of:
- the retinoid X receptor antagonist is selected from the group consisting of:
- LGN100572 LGN100574, l-(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)ethanone, l-(3-propoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)ethanone,
- the Vitamin D receptor antagonist is selected from the group consisting of: 1 alpha, 25-(OH)-D3-26,23 lactone; 1 alpha, 25-dihydroxyvitamin D (3); the 25-carboxylic ester ZK159222; (23S)- 25-dehydro-l alpha-OH-D (3); (23R)-25-dehydro-l alpha-OH-D (3); 1 beta, 25 (OH) 2 D 3 ; 1 beta, 25(OH) 2 -3-epi-D 3 ; (23S) 25-dehydro-l alpha(OH) D3-26,23-lactone; (23R) 25-dehydro-l alpha(OH)D3-26,23-lactone and Butyl-(5Z,7E,22E-(lS,7E,22E-(lS,3R,24R)-l,3,24-trihydroxy-26,27-cyclo-9,10 -secocholesta-5,7,10(19)
- the present invention successfully addresses the shortcomings of the presently known configurations by providing a method of propagating cells, yet delaying their differentiation by interference with CD38 expression and/or activity, or with retinoic acid, retinoid X and/or Vitamin D receptor signaling.
- the present invention further successfully addresses the shortcomings of the presently known configurations by enabling, for the first time, expansion of renewable stem cells in the presence of committed cells, so as to obtain an expanded population of renewable stem cells, albeit their origin from a mixed population of cells, in which they constitute a fraction of a percent.
- FIG. 1A is a FACS analysis plot showing control cell surface marker expression with liberal expression of CD34, CD38 and lineage-related antigens.
- FIG. IB is a FACS analysis plot showing RAR antagonist (10 "5 M) treated culture cell surface marker expression with a similar level of expression of the CD34 antigen, but an almost complete abrogation of the CD38 and lineage-related antigen expression, as compared to controls.
- FIG. IC is a FACS analysis plot showing RAR antagonist (10 6 M) treated culture cell surface marker expression with a similar level of expression of the CD34 antigen, but an almost complete abrogation of the CD38 and lineage-related antigen expression, as compared to controls.
- FIG. 2A is a graph of data collected by FACS analysis showing comparable CD34 + cell expansion levels in control and RAR antagonist treated cultures.
- FIG. 2B is a graph of data collected by FACS analysis showing markedly enhanced CD34 + CD38 " cell expansion levels in response to RAR antagonist treatment, at either the 10 " or 10 " M concentrations, as compared to controls.
- FIG. 2C is a graph of data collected by FACS analysis showing markedly enhanced CD34 + Lin “ cell expansion levels in response to RAR antagonist treatment, at either the 10 " or 10 " M concentrations, as compared to controls.
- FIG. 3A is a graph of data collected by FACS analysis revealing comparable CD34 + surface expression up to 2 weeks post seeding of control and treated cultures.
- Cultures were treated with an RAR antagonist, 10 "5 M and 10 "7 M [or 41 ⁇ g/liter to 0.41 ⁇ g/liter] and a combination of 4 cytokines (IL-6, TPO, FLT3 and SCF), and were subjected to an additional positive selection step prior to FACS analysis.
- a marked increase in expression is seen, however, 9 and 1 1 weeks post seeding in cultures treated with RAR antagonists, as compared to controls.
- 3B is a graph of data collected by FACS analysis showing comparable CD34 + CD38 " surface expression up to 2 weeks post seeding of control and RAR antagonist and cytokine treated cultures, (as treated in 3A), in samples subjected to an additional positive selection step. A marked increase in expression is seen 9 and 11 weeks post seeding in RAR antagonist treated cultures, as compared to controls.
- FIG. 3C is a graph of data collected by FACS analysis showing enhanced CD34 + Lin " surface expression by 2 weeks post seeding of RAR antagonist treated cultures, (as treated in 3A), as compared to controls, in samples subjected to an additional positive selection step. A markedly increased expression is seen in the groups treated with RAR antagonist by 9 and 11 weeks post seeding.
- FIG. 4 is a graph of data collected by FACS analysis and LTC-CFU ability showing high levels of CD34 + cell proliferation and long-term colony forming unit ability in ex-vivo cultures treated with 10 " M of the RAR antagonist and a combination of the 4 cytokines, as above, up to almost 12 weeks post seeding. At 10 weeks and 11 weeks (CFUs and CD34 cells, respectively), these populations begin to decline.
- FIG. 5A is a FACS analysis plot of the negative control showing no background staining.
- FIG. 5B is a FACS analysis plot of the positive control of reselected cell cultures showing ample CD34 + cell surface staining.
- FIG. 5C is a FACS analysis plot of the RAR antagonist treated cultures 2 weeks post reselection showing a marked leftward shift in profile, consistent with a less differentiated state.
- FIG. 5D is a FACS analysis plot of the RAR antagonist treated cultures (10 "7 ) 11 weeks post reselection showing ample CD34 + cell surface staining, and a profile consistent with a more differentiated state.
- FIG. 5E is a FACS analysis plot of the RAR antagonist treated cultures (10 ⁇ 5 ) 11 weeks post reselection showing a marked leftward shift in profile, consistent with a less differentiated state.
- FIG. 6A is a graph of colony forming unit data showing that both long-term cultures pulsed for the first 3 weeks with the antagonists or cultures administered RAR antagonists continuously reveal a 5-fold increase in CFU content as compared to control values.
- FIG. 6B is a graph of cell enumeration data showing that long-term cultures either pulsed for the first 3 weeks with antagonists, or administered RAR antagonists continuously, reveal a 5-fold increase in CFU content as compared to control values.
- FIG. 7 is a graph of mixed colony forming unit data showing that both long-term cultures pulsed for the first 3 weeks with the antagonists or cultures administered RAR antagonists continuously reveal a dramatic increase in CFU content as compared to control values, with pulse-treatment yielding the highest
- FIG. 8A is a photomicrograph of three weeks old primary hepatocyte cultures isolated from mice. Hepatocytes were probed for expression of ⁇ -fetoprotein (AFP) and counterstained with hematoxylin. Moderate AFP staining is evident (red-brown precipitate).
- AFP ⁇ -fetoprotein
- FIG. 8B is a photomicrograph of three week old primary hepatocyte cultures isolated from mice. Hepatocytes were incubated in the presence of 10 "5 M retinoic acid receptor antagonist (AGN 194310) and were similarly probed for AFP expression and counterstained with hematoxylin. AGN 194310-treated hepatocytes revealed a marked increase in AFP expression, as compared to controls.
- FIG. 9A is a photomicrograph of giemsa stained, three week old, primary murine hepatocyte cultures revealing cell mo ⁇ hology. Few oval cells were noted in this sample (thick arrow), in contrast to numerous hepatocytes with typical mo ⁇ hology (narrow arrow)
- FIG. 9B is a photomicrograph of giemsa stained, primary hepatocyte cultures incubated in the presence of 10 "5 M retinoic acid receptor antagonist (AGN 194310). Antagonist treated cells showed a marked increase in oval cell population (arrow).
- FIG. 9C is a photomicrograph of giemsa stained, primary hepatocyte cultures incubated in the presence of 10 "5 M retinoic acid receptor antagonist (AGN 194310) followed by trypsinization and replating, at a ratio of 1:2, in a culture medium devoid of cytokines. These cultures similarly revealed characteristic hepatocyte mo ⁇ hology
- FIG. 10A is a photomicrograph of three weeks old primary hepatocyte cultures isolated from mice, and supplemented with EGF (20 ng/ml) and HGF (20 ng/ml). Hepatocytes were treated with RAR antagonist AGN 194310 at 10 " M to 10 " M, probed for expression of albumin and counterstained with hematoxylin. There is no appreciable background staining. Indicated that the cells expanded in cultures supplemented with the antagonist are hepatocytes by nature.
- FIG. 10B is a photomicrograph of three weeks old primary hepatocyte control cultures isolated from mice, similarly supplemented with EGF and HGF and probed for albumin expression. Negligible background staining is evident here as well.
- FIG. 10C is a photomicrograph of three weeks old primary hepatocyte
- FIG. 10D is a photomicrograph of three weeks old primary hepatocyte control cultures isolated from mice, similarly supplemented with EGF and HGF and probed for ⁇ -fetoprotein expression. Negligible staining is evident indicating a more differentiated cellular phenotype. All figures were photographed at lOx/0.3 magnification.
- FIG. 11A is a photomicrograph of first passage heaptocyte control cultures isolated from mice and supplemented with EGF and HGF, split 1:2 following 2 weeks in culture and cultured for an additional week prior to probing for albumin expression, as above. Numerous typical hepatocytes (small arrow) are evident.
- FIG. 1 IB is a photomicrograph of first passage RAR antagonist AGN
- 194310 (10 5 - 10 "7 M) treated heaptocyte cultures isolated from mice cultured as in A and probed for albumin expression. Typical hepatocyte mo ⁇ hology (small arrow) is evident in this frame as well.
- FIG. 11C is a photomicrograph of first passage RAR antagonist treated hepatocyte cultures, cultured and probed as in B. Numerous characteristic oval cells are evident (large arrow) in the field. Magnification - 20x/0.5.
- FIG. 1 ID is a photomicrograph is a lower magnification of Figure 11C, revealing numerous islets of oval cells in the RAR antagonist treated cultures, consistent with a less-differentiated phenotype.
- FIG. HE is a photomicrograph of second passage heaptocyte control cultures isolated from mice and supplemented with EGF and HGF, split 1 :2 following 2 weeks in culture, cultured for an additional week prior to 1 :4 split, and following a final additional 4 day culture, probing for albumin expression, as above. Few hepatocytes are evident.
- FIG. 1 IF is a photomicrograph of similarly isolated and cultured second passage heaptocyte cultures treated with RAR antagonist AGN 194310 (10 "5 M to 10 "7 M). Significantly greater numbers of hepatocytes are evident in the cultures as compared to controls. Magnification - 20x/0.5.
- FIG. 12A is a plot presenting the FACS analysis of cultures treated with cytokines only (control), RAR antagonist AGN 194310 (10 7 M) and a combination of RAR antagonist (10 7 M) and RXR antagonist, 3 weeks post reselection. A marked leftward shift in profile of the combined, RAR and RXR antagonists, treatment, consistent with a less differentiated state, as compared with the untreated control and the RAR antagonist treatment is demonstrated.
- FIG. 12B is a plot presenting a FACS analysis of cultures treated with cytokines only (control), RAR antagonist AGN 194310 (10 "7 M), RXR antagonist LGN 100754 (10 "7 M) and a combination of RAR and RXR antagonists (10 "? M), 5 weeks post reselection. A marked leftward shift in profile of the combined, RAR and RXR antagonists, treatment, consistent with a less differentiated state, as compared with the RAR antagonist treatment is demonstrated.
- FIG. 13A is a bar graph presenting the data obtained by FACS analysis of cultures treated with a RAR antagonist AGN 194310, a RXR antagonist LGN 100754 and a combination thereof. Comparable CD34 + surface expression levels determined 3 and 5 weeks post seeding are evident. A marked increase in expression in cultures treated with a combination of the RAR and RXR antagonists, as compared with the untreated (cytokines only) control, the RAR antagonist and RXR antagonist treatments is demonstrated.
- FIG. 13B is a bar graph presenting the data obtained by FACS analysis of cultures treated with an RAR antagonist AGN 194310, an RXR antagonist LGN 100754 and a combination thereof. Comparable CD34 + /38 " surface expression levels determined 3 and 5 weeks post seeding are evident. A marked increase in expression in cultures treated with the combination of RAR and RXR antagonists, as compared with the untreated control (cytokines only), the RAR antagonist and the RXR antagonist treatments is demonstrated.
- FIG. 13C is a bar graph presenting the data obtained by FACS analysis of cultures treated with an RAR antagonist AGN 194310, an RXR antagonist LGN 100754 and a combination thereof. Comparable CD34 + /Lin " surface expression levels determined 3 and 5 weeks post seeding are evident. A marked increase in expression in cultures treated with the RAR and RXR antagonists combination, as compared with the untreated control (cytokines only), the RAR antagonist and the RXR antagonist treatments is demonstrated.
- FIG. 13D is a bar graph presenting the total cell density of cultures treated with an RAR antagonist AGN 194310, an RXR antagonist LGN 100754 and a combination thereof. Comparable number of cells determined 3 and 5 weeks post seeding is evident. A significant increase of cell density in cultures treated with RAR+RXR antagonist 5 weeks post seeding, as compared with the untreated control (cytokines only), the RAR antagonist and RXR antagonist treatments is demonstrated.
- FIG. 13E is a bar graph presenting the colony- forming unit (CFU) data of cultures treated with an RAR antagonist AGN 194310, an RXR antagonist LGN 100754 and a combination thereof. Comparable CFU levels determined 3 and 5 weeks post seeding are evident. A marked increase in CFU in cultures treated with the RAR and RXR combination, as compared with the untreated control (cytokines only), the RAR antagonist and the RXR antagonist treatments is demonstrated.
- CFU colony- forming unit
- FIG. 14 is a bar graph presenting the density of CD34+ cells enumerated in 3 weeks culture.
- the cell culture was supplemented with SCF, TPO, FLt3, IL-6 and IL-3 cytokines, with or without nicotinamide at 1 mM and 5 mM concentrations.
- a marked increase in CD34+ cells density in the nicotinamide treated cultures is demonstrated.
- FIG. 15 is a bar graph presenting the data obtained by FACS analysis of CD34+/CD38- cells in 3 weeks culture.
- the cell culture was supplemented with SCF, TPO, FLt3, IL-6 and IL-3 cytokines, with or without nicotinamide at 1 mM and 5 mM concentrations.
- SCF SCF
- TPO TPO
- FLt3 IL-6
- IL-3 cytokines
- FIG. 16 is a bar graph presenting the data obtained by FACS analysis of CD34+/Lin- cells in 3 weeks culture.
- the cell culture was supplemented with SCF, TPO, FLt3, IL-6 and IL-3 cytokines, with or without nicotinamide at 1 mM and 5 mM concentrations.
- SCF SCF
- TPO TPO
- FLt3 IL-6
- IL-3 cytokines
- FIG. 17 is a bar graph presenting the data obtained by FACS analysis of CD34+/(HLA-DR38)- cells in 3 weeks culture.
- the cell culture was supplemented with SCF, TPO, FLt3, IL-6 and IL-3 cytokines, with or without nicotinamide at 1 mM and 5 mM concentrations.
- SCF SCF
- TPO TPO
- FLt3 FLt3
- IL-6 IL-3 cytokines
- FIG. 18a is a dot plot presenting a FACS analysis of re-selected CD34+ cells from a 3 weeks culture treated with cytokines, with or without 5 mM nicotinamide.
- the CD34+/CD38- cells are shown in the upper left part of the plot, demonstrating a marked increase of CD34+/CD38- cells in the nicotinamide treated culture.
- FIG. 18b is a dot plot presenting a FACS analysis of re-selected CD34+ cells from a 3 weeks culture treated with cytokines, with or without 5 mM nicotinamide, 3 weeks post reselection.
- the CD34+/Lin- cells are shown in the upper left part of the plot, demonstrating a marked increase of CD34+/Lin- cells in the nicotinamide treated culture.
- FIG. 18c is a dot plot presenting a FACS analysis of re-selected CD34+ cells from a 3 weeks culture treated with cytokines, with or without 5 mM nicotinamide, 3 weeks post reselection.
- the CD34+/(HLA-DR38)- cells are shown in the upper left part of the plot, demonstrating a marked increase of
- CD34+/+/(HLA-DR38)- cells in the nicotinamide treated culture CD34+/+/(HLA-DR38)- cells in the nicotinamide treated culture.
- the present invention is of methods of expanding a population of stem cells, while at the same time, substantially inhibiting differentiation of the cells ex-vivo and/or in-vivo.
- the invention facilitates the efficient use as a therapeutic ex-vivo cultured cell preparation, which includes an expanded, large population of renewable stem cells, in which differentiation was inhibited while cell expansion was propagated.
- the present invention can be used to provide ex-vivo expanded populations of stem cells, which can be used for applications in hematopoietic cell transplantations, and in generation of stem cells suitable for genetic manipulations, which may be used for cellular gene therapy.
- Additional applications may include, but are not limited to, adoptive immunotherapy, treatments for multiple diseases, such as, for example, ⁇ -hemoglobinopathia, implantation of stem cells in an in vivo cis-differentiation and trans-differentiation settings, and ex vivo tissue engineering in cis-differentiation and trans-differentiation settings.
- the present invention further relates to expanded stem cell preparations and to articles-of-manufacture for preparing same.
- the present invention discloses the use of various molecules (also referred to herein as agents), for interfering with CD38 expression and/or activity, thereby inducing ex-vivo expansion of stem cell populations, resulting, when applied, for example, to hematopoietic stem cells, in large numbers of undifferentiated CD34 + /Lin " (CD33, CD14, CD15, CD4, etc.), as well as CD34 + /CD38 " cells, especially CD34 + dim /Lin " cells.
- This novel and versatile technology may be used for ex-vivo and/or in-vivo expansion of stem cells, of hematopoietic and other origins, maintaining their self-renewal potential for any in-vivo or ex-vivo application which requires a large population of stem cells.
- CD38 is a member of an emerging family of cytosolic and membrane-bound enzymes whose substrate is nicotinamide adenine dinucleotide (NAD).
- NAD nicotinamide adenine dinucleotide
- cADPR and NAADP Two of the metabolites produced by CD38, cADPR and NAADP, have been shown to induce the release of intracellular calcium in cells isolated from tissues of plants, invertebrates and mammals, suggesting that these metabolites may be global regulators of calcium responses (Lee et al., 1999 Biol. Chem. 380;785-793).
- CD38 signaling was achieved by using mo ⁇ holino antisense oligonucleotides targeting its mRNA, which produced a corresponding inhibition of differentiation as well (Munshi CB, Graeff R, Lee HC, J Biol Chem 2002 Dec 20;277(51):49453-8).
- Other studies have shown an opposite effect of CD38 signaling on progenitor cell differentiation. Short term treatment of human progenitor cells with cADPR mediated a significant increase in colony size and colony output, implying a direct correlation between CD38 signaling and ex-vivo stem cell expansion (Podesta (2000) FASEB J. 14:680-690).
- Retinoid receptors such as RAR, RXR and VDR and their agonists, such as Vitamin A and it's active metabolites and Vitamin D and it's active metabolites are involved in the regulation of gene expression pathways associated with cell proliferation and differentiation.
- Vitamin D which was shown to be a differentiation inducer of myelomonocytic cells, transduces its signals via induction of hetrodimerization of the RXR- VDR retinoid receptors (28), whereas RAR-RXR or RXR-RXR hetrodimerization is essential for retinoids inducing granulocytic differentiation.
- retinoid-deficient tissues acquire a pre-malignant phenotype, which is characterized by enhanced mitotic activity and loss of differentiation (30).
- the RAR- ⁇ gene is expressed in normal epithelial tissue, where its expression is up-regulated by treatment with retinoic acid (31, 32).
- retinoic acid 31, 32.
- the level of RAR- ⁇ 2 mRNA is decreased or undetectable (33-37), indicating that the specific loss of RAR- ⁇ 2 mRNA expression may be an important event in tumorogenesis.
- RAR retinoic acid receptor
- RAR activity is ligand concentration-dependent, then what is the mechanism by which RAR activity regulates myeloid differentiation of cells that are exposed to the uniform "physiological" concentrations of retinoids that are presumably present in blood and bone marrow? Most importantly from a clinical standpoint, why do only the acute pro-myelocytic leukemic cells (APL) exhibit a dramatic response to retinoids while the other 90 % of acute myelogenous leukemias do not, even though these other acute myelogenous leukemias express normal RARs (40)? The biological effect of retinoids and retinoid receptors on normal, non-leukemic, hematopoietic stem cells was reported by Purton et al. (41).
- Purton et al. (41) demonstrated that pharmacological levels (1 ⁇ mol) of all-trans-retinoic-acid (ATRA) enhanced the generation of colony-forming cell (CFC) and colony-forming unit-spleen (CFU-S) in liquid suspension cultures of Lin ' c-kit + Sca-1 + murine hematopoietic precursors.
- ATRA all-trans-retinoic-acid
- CFC colony-forming cell
- CFU-S colony-forming unit-spleen
- AGN 193109 an RAR antagonist
- retinoids accelerates the growth and differentiation of granulocyte progenitors in cytokine-stimulated cultures of purified CD34 + cells (42), at the stem cell level, the retinoids show an opposite effect.
- leukemia cell line models such as HL-60, NH4, and 32D, which are lineage committed cells that are blocked at the myeloblast or promyelocytic stage of differentiation, inactivation of these receptors by specific antagonists, antisense or transduction with truncated receptors is associated with inhibition of induced granulocytic and monocytic differentiation.
- CD34 + antigen is expressed on committed as well as multi potent stem cells. Only a small fraction of the entire CD34 + cell population, the CD34 + /CD38 " and CD34 + /Lin " cells, belong to the stem and early progenitor cell compartment.
- CFU-mix impressively increased as compared to the content of CFU in cultures treated only with the cytokines, which actually decreases during the long-term cultures. In fact, many of the control cultures were unable to maintain any CFU potential in the long and extended long-term culture. In contrast to cultures treated for 3 weeks with the antagonist, which showed a dramatic and continuous increase of CFU-mix during the extended long-term culture period, cytokine-only treated cultures did not enable the expansion or even the maintenance of mix-colonies during the entire culture period. Expansion of stem cells, as revealed from the phenotype characterization, is in complete agreement with the long-term self-renewal potential as measured by the functional LTC-CFUc assay.
- retinoid receptors are involved in the regulation of stem cell self-renewal. It is further demonstrated herein that the addition of these molecules for only a limited, short-term period to the ex-vivo cultures media enables the continuous proliferation of stem cells with no alteration of their phenotype for extended time periods. Furthermore, these effects of retinoic acid receptor antagonists did not involve any cell transformation and do not result in any cell line formation.
- retinoic acid an active metabolite of vitamin A
- Retinoids are also long known to influence skin mo ⁇ hology.
- antagonists to RAR are given late in gestation, 14 days post conception (dpc), they delay differentiation and maturation of the fetal skin and hair follicles in mouse (65).
- RXR-alpha ablation results in epidermal interfollicular hype ⁇ lasia with keratinocyte hype ⁇ roliferation and aberrant terminal differentiation, accompanied by an inflammatory reaction of the skin.
- RXR-alpha/VDR heterodimers play a major role in controlling hair cycling, and suggested that additional signaling pathways mediated by RXR-alpha heterodimerized with other nuclear receptors are involved in postnatal hair follicle growth (66).
- the novel method of ex-vivo down-regulation of cell differentiation enabled large expansion of embryonic and adult, hematopoietic and non-hematopoietic stem cells and may be utilized for transplantation of hematopoietic cells, gene therapy, cell replacement therapy or any other application, which requires increasing numbers of stem cells.
- Hematopoietic cell transplantation Transplantation of hematopoietic cells has become the treatment of choice for a variety of inherited or malignant diseases. While early transplantation procedures utilized the entire bone marrow (BM) population, recently, more defined populations, enriched for stem
- CD34 cells have been used (44).
- such cells could be derived from other sources such as peripheral blood (PB) and neonatal umbilical cord blood (CB) (45).
- PB peripheral blood
- CB neonatal umbilical cord blood
- transplantation with PB cells shortens the period of pancytopenia and reduces the risks of infection and bleeding (46-48).
- An additional advantage of using PB for transplantation is its accessibility.
- the limiting factor for PB transplantation is the low number of circulating pluripotent stem progenitor cells.
- PB-derived stem cells To obtain enough PB-derived stem cells for transplantation, these cells are "harvested" by repeated leukophoresis following their mobilization from the marrow into the circulation by treatment with chemotherapy and cytokines
- the cultures provide a significant depletion of T lymphocytes, which may be useful in the allogeneic transplant setting for reducing graft- versus-host disease.
- ex-vivo expanded cells include, in addition to stem cells, more differentiated progenitor cells in order to optimize short-term recovery and long term restoration of hematopoiesis. Expansion of intermediate and late progenitor cells, especially those committed to the neutrophilic and megakaryocytic lineages, concomitant with expansion of stem cells, should serve this pu ⁇ ose (51).
- Such cultures may be useful in restoring hematopoiesis in recipients with completely ablated bone marrow, as well as in providing a supportive measure for shortening recipient bone marrow recovery following conventional radio- or chemo-therapies.
- Prenatal diagnosis of genetic defects in scarce cells involves the collection of embryonic cells from a pregnant woman, in utero, and analysis thereof for genetic defects.
- a preferred, non-invasive, means of collecting embryonic cells involves separation of embryonic nucleated red blood cell precursors that have infiltrated into peripheral maternal circulation.
- Gene therapy For successful long-term gene therapy, a high frequency of genetically modified stem cells with transgenes stably integrated within their genome, is an obligatory requirement.
- stem cells In BM tissue, while the majority of cells are cycling progenitors and precursors, stem cells constitute only a small fraction of the cell population and most of them are in a quiescent, non-cycling state.
- Niral-based (e.g., retroviral) vectors require active cell division for integration of the transgene into the host genome. Therefore, gene transfer into fresh BM stem cells is highly inefficient. The ability to expand a purified population of stem cells and to regulate their cell division ex-vivo would provide for an increased probability of their genetic modification (52).
- Adoptive immunotherapy Ej -v/v ⁇ -expanded, defined lymphoid subpopulations have been studied and used for adoptive immunotherapy of various malignancies, immunodeficiencies, viral and genetic diseases (53-55).
- Additional applications of the technology proposed herein include the possibility for ex-vivo expansion of non-hematopoietic stem and progenitor cells, including, for example, neural stem cells, oligodendrocyte progenitors, and the like.
- U.S. Pat. No. 5,736,396 provides methods for in-vitro or ex-vivo lineage-directed induction of isolated, culture-expanded human mesenchymal stem cells comprising mesenchymal stem cell contact with a bioactive factor effective in inducing stem cell differentiation into a lineage of choice. Further disclosed is a method including introducing culture-expanded lineage-induced mesenchymal stem cells into the original, autologous host, for pu ⁇ oses of mesenchymal tissue regeneration or repair.
- U.S. Pat. No. 4,642,120 provides compositions for repairing defects in cartilage and bones. These are provided in gel form either as such, or embedded in natural or artificial bones.
- the gel comprises certain types of cells.
- Cells may be committed embryonal chondrocytes or any mesenchymal-origin cells which potentially can be converted to become functional cartilage cells, typically by the inclusion of chondrogenic inducing factors, in combination with fibrinogen, antiprotease and thrombin.
- U.S. Pat. No. 5,654,186 illustrates that blood-borne mesenchymal cells proliferate in culture, and in-vivo, as demonstrated in animal models, and are capable of migrating into wound sites from the blood to form skin.
- U.S. Pat. No. 5,716,411 reveals a method of skin regeneration of a wound or burn in an animal or human. This method comprises the steps of initially covering the wound with a collagen glycosaminoglycan (GC) matrix, facilitating mesenchymal cell and blood vessel infiltration from healthy underlying tissue within the grafted GC matrix. Subsequently a cultured epithelial autograft sheet grown from epidermal cells taken from the animal or human at a wound-free site is applied on the body surface. The resulting graft has excellent inclusion rates and has the appearance, growth, maturation and differentiation of normal skin.
- U.S. Pat. No. 5,716,616 provides methods for treating recipients suffering from diseases, disorders or conditions characterized by bone, cartilage, or lung defects.
- the methods comprise intravenous administration of stromal cells isolated from normal, syngeneic individuals, or intravenous administration of stromal cells isolated from the recipient subsequent to correction of the genetic defect in the isolated cells.
- Methods of introducing genes into a recipient individual are also disclosed.
- the methods comprise obtaining a bone marrow sample from either the recipient individual or a matched syngeneic donor and isolating adherent cells from the sample. Once isolated, donor adherent cells are transfected with a gene and administered to a recipient individual intravenously.
- Compositions comprising isolated stromal cells that include exogenous genes operably linked to regulatory sequences are disclosed, as well.
- non-hematopoietic stem and progenitor cells are used as an external source of cells for replenishing missing or damaged cells of an organ.
- Such use requires high levels of stem and progenitor cell expansion for successful application of the proposed therapies.
- the methods and applications of the present invention address a critical niche in any of the methods disclosed in the above U.S. patents. Additional examples for both ex-vivo and in-vivo applications:
- stem and progenitor cell expansion include skin regeneration, hepatic regeneration, muscle regeneration and stimulation of bone growth for applications in osteoporosis.
- Fetal hemoglobin which normally comprises 1 % of the total hemoglobin, becomes elevated in accelerated erythropoiesis (e.g., following acute hemolysis or hemorrhage or administration of erythropoietin) (62). It has been suggested that this phenomenon is associated with acceleration of the maturation/differentiation process of erythroid precursors (63).
- Administration of retinoic acid, retinoid and/or Vitamin D receptor antagonists to recipients with ⁇ -hemoglobinopathies might first increase and synchronize their early erythroid progenitor pool, by blocking progenitor differentiation.
- a method of ex-vivo expanding a population of stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo is effected by providing the stem cells with ex-vivo culture conditions for ex-vivo cell proliferation and, at the same time, for reducing an expression and/or activity of CD38, thereby expanding the population of stem cells while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- stem cells refers to pluripotent cells that, given the right growth conditions, may develop to any cell lineage present in the organism from which they were derived.
- the phrase, as used herein, refers both to the earliest renewable cell population responsible for generating cell mass in a tissue or body and the very early progenitor cells, which are somewhat more differentiated, yet are not committed and can readily revert to become a part of the earliest renewable cell population.
- Methods of ex-vivo culturing stem cells of different tissue origins are well known in the art of cell culturing. To this effect, see for example, the text book "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition, the teachings of which are hereby inco ⁇ orated by reference.
- inhibiting refers to slowing, decreasing, delaying, preventing or abolishing.
- differentiation refers to relatively generalized or specialized changes during development. Cell differentiation of various lineages is a well-documented process and requires no further description herein. As used herein the term differentiation is distinct from maturation which is a process, although some times associated with cell division, in which a specific cell type mature to function and then dies, e.g., via programmed cell death.
- cell expansion is used herein to describe a process of cell proliferation substantially devoid of cell differentiation. Cells that undergo expansion hence maintain their cell renewal properties and are oftentimes referred to herein as renewable cells, e.g., renewable stem cells.
- ex-vivo refers to a process in which cells are removed from a living organism and are propagated outside the organism (e.g., in a test tube).
- ex-vivo does not refer to a process by which cells known to propagate only in-vitro, such as various cell lines (e.g., HL-60, MEL, HeLa, etc.) are cultured.
- cells expanded ex-vivo according to the present invention do not transform into cell lines in that they eventually undergo differentiation.
- Providing the ex-vivo grown cells with conditions for ex-vivo cell proliferation include providing the cells with nutrients and preferably with one or more cytokines, as is further detailed hereinunder.
- the cells are short-term treated or long-term treated to reduce the expression and/or activity of CD38.
- CD38 inhibitor refers to an agent which is capable of down-regulating or suppressing CD38 activity in stem cells.
- a CD38 inhibitor according to this aspect of the present invention can be a "direct inhibitor” which inhibits CD38 intrinsic activity or an “indirect inhibitor” which inhibits the activity or expression of CD38 signaling components (e.g., the cADPR and ryanodine signaling pathways) or other signaling pathways which are effected by CD38 activity.
- CD38 signaling components e.g., the cADPR and ryanodine signaling pathways
- nicotinamide is a preferred CD38 inhibitor.
- the method according to this aspect of the present invention is effected by providing the cells either with nicotinamide itself, or with a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite.
- nicotinamide analog refers to any molecule that is known to act similarly to nicotinamide.
- Representative examples of nicotinamide analogs include, without limitation, benzamide, nicotinethioamide (the thiol analog of nicotinamide), nicotinic acid and ⁇ -amino-3-indolepropionic acid.
- a nicotinamide or a nicotinamide analog derivative refers to any structural derivative of nicotinamide itself or of an analog of nicotinamide. Examples of such derivatives include, without limitation, substituted benzamides, substituted nicotinamides and nicotinethioamides and
- N-substituted nicotinamides and nicotinthioamides N-substituted nicotinamides and nicotinthioamides.
- a nicotinamide or a nicotinamide analog metabolite refers to products that are derived from nicotinamide or from analogs thereof such as, for example, NAD, NADH and NADPH.
- a CD38 inhibitor according to this aspect of the present invention can be an activity neutralizing antibody which binds for example to the CD38 catalytic domain, thereby inhibiting CD38 catalytic activity.
- CD38 is an intracellular protein measures are taken to use inhibitors which may be delivered through the plasma membrane.
- a fragmented antibody such as a Fab fragment (described hereinunder) is preferably used.
- antibody as used in this invention includes intact molecules as well as functional fragments thereof, such as Fab, F(ab') 2 , and Fv that are capable of binding to macrophages. These functional antibody fragments are defined as follows:
- Fab the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain;
- Fab' the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (Fab') 2 , the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab') 2 is a dimer of two Fab' fragments held together by two disulfide bonds;
- Fv defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains;
- Single chain antibody a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
- Antibody fragments according to the present invention can be prepared by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment.
- mammalian cells e.g. Chinese hamster ovary cell culture or other protein expression systems
- Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods.
- antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab') .
- This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
- an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly.
- Fv fragments comprise an association of V H and V L chains. This association may be noncovalent, as described in Inbar et al., Proc. Nat'l Acad. Sci. USA 69:2659-62, 1972.
- the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde.
- the Fv fragments comprise V H and V L chains connected by a peptide linker.
- sFv single-chain antigen binding proteins
- the structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli.
- the recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains.
- Methods for producing sFvs are described, for example, by Whitlow and Filpula, Methods, 2: 97-105, 1991; Bird et al., Science 242:423-426, 1988; Pack et al., Bio/Technology 11:1271-77, 1993; and Ladner et al., U.S. Pat. No. 4,946,778, which is hereby inco ⁇ orated by reference in its entirety.
- CDR peptides (“minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry, Methods, 2: 106-10, 1991.
- Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
- Humanized antibodies include human immunoglobulins recipient antibody in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
- CDR complementary determining region
- donor antibody such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
- Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
- Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
- the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
- the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].
- Fc immunoglobulin constant region
- a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321 :522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
- humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
- humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
- Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol.
- human can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos.
- the method according to this aspect of the present invention can be effected by providing the ex-vivo cultured stem cells with an agent that down-regulates CD38 expression.
- An agent that downregulates CD38 expression refers to any agent which affects CD38 synthesis (decelerates) or degradation (acelerates) either at the level of the mRNA or at the level of the protein.
- a small interfering polynucleotide molecule which is designed to down regulate the expression of CD38 can be used according to this aspect of the present invention.
- RNA or siRNA such as, for example, the mo ⁇ holino antisense oligonucleotides described by in Munshi et al. (Munshi CB, Graeff R, Lee HC, J Biol Chem 2002 Dec 20;277(51):49453-8), which includes duplex oligonucleotides which direct sequence specific degradation of mRNA through the previously described mechanism of RNA interference (RNAi) (Hutvagner and Zamore (2002) Curr. Opin. Genetics and Development 12:225-232).
- RNAi RNA interference
- duplex oligonucleotide refers to an oligonucleotide structure or mimetics thereof, which is formed by either a single self-complementary nucleic acid strand or by at least two complementary nucleic acid strands.
- the "duplex oligonucleotide” of the present invention can be composed of double-stranded RNA (dsRNA), a DNA-RNA hybrid, single-stranded RNA (ssRNA), isolated RNA (i.e., partially purified RNA, essentially pure RNA), synthetic RNA and recombinantly produced RNA.
- the specific small interfering duplex oligonucleotide of the present invention is an oligoribonucleotide composed mainly of ribonucleic acids.
- the small interfering polynucleotide molecule according to the present invention can be an RNAi molecule (RNA interference molecule).
- a small interfering polynucleotide molecule can be an oligonucleotide such as a CD38-specific antisense molecule or a rybozyme molecule, further described hereinunder.
- Oligonucleotides designed according to the teachings of the present invention can be generated according to any oligonucleotide synthesis method known in the art such as enzymatic synthesis or solid phase synthesis. Equipment and reagents for executing solid-phase synthesis are commercially available from, for example, Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the capabilities of one skilled in the art. Oligonucleotides used according to this embodiment of the present invention are those having a length selected from a range of 10 to about 200 bases preferably 15-150 bases, more preferably 20-100 bases, most preferably 20-50 bases.
- the oligonucleotides of the present invention may comprise heterocyclic nucleosides consisting of purines and the pyrimidines bases, bonded in a 3' to 5' phosphodiester linkage.
- oligonucleotides are those modified in either backbone, internucleoside linkages or bases, as is broadly described hereinunder. Such modifications can oftentimes facilitate oligonucleotide uptake and resistivity to intracellular conditions.
- oligonucleotides useful according to this aspect of the present invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone, as disclosed in U.S.
- Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.
- modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
- oligonucleotides which can be used according to the present invention, are those modified in both sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups.
- the base units are maintained for complementation with the appropriate polynucleotide target.
- An example for such an oligonucleotide mimetic includes peptide nucleic acid (PNA).
- PNA peptide nucleic acid
- a PNA oligonucleotide refers to an oligonucleotide where the sugar-backbone is replaced with an amide containing backbone, in particular an aminoethylglycine backbone.
- the bases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
- Modified bases include but are not limited to other synthetic and natural bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted ura
- 5-substituted pyrimidines include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
- 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 °C. [Sanghvi YS et al. (1993) Antisense Research and Applications, CRC Press, Boca Raton 276-278] and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.
- oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide.
- moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium l,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl
- the oligonucleotides of the present invention are preferably antisense molecules, which are chimeric molecules.
- "Chimeric antisense molecules” are oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target polynucleotide. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.
- RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex.
- Activation of RNase H therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region.
- Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
- Chimeric antisense molecules of the present invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, as described above.
- Representative U.S. patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat.
- the oligonucleotides of the present invention can further comprise a ribozyme sequence.
- Rybozymes are being increasingly used for the sequence-specific inhibition of gene expression by the cleavage of mRNAs.
- rybozyme sequences can be fused to the oligonucleotides of the present invention. These sequences include but are not limited ANGIOZYME specifically inhibiting formation of the VEGF-R (Vascular Endothelial Growth
- HEPTAZYME a rybozyme designed to selectively destroy Hepatitis C Virus
- HCV HCV RNA
- Synzyme Pharmaceuticals Inco ⁇ orated - WEB home page
- a small interfering polynucleotide molecule can be a DNAzyme.
- DNAzymes are single-stranded catalytic nucleic acid molecules.
- a general model (the "10-23" model) for the DNAzyme has been proposed.
- DNAzymes have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each. This type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions (Santoro, S.W. & Joyce, G.F.
- DNAzymes recognizing single and double-stranded target cleavage sites have been disclosed in U.S. Pat. No. 6,326,174 to Joyce et al. DNAzymes of similar design directed against the human Urokinase receptor were recently observed to inhibit Urokinase receptor expression, and successfully inhibit colon cancer cell metastasis in vivo (Itoh et al , 20002, Abstract 409, Ann Meeting Am Soc Gen Ther www.asgt.org). In another application, DNAzymes complementary to bcr-abl oncogenes were successful in inhibiting the oncogenes expression in leukemia cells, and lessening relapse rates in autologous bone marrow transplant in cases of CML and ALL.
- retinoid receptor superfamily inhibitors e.g., antagonists, siRNA molecules, antisense molecules, antibodies, etc.
- retinoid receptor superfamily inhibitors which downregulate or suppress retinoid receptor activity and/or expression can be used to down regulate CD38 expression.
- retinoid receptors such as RAR, RXR and VDR have been reported to be involved in the regulation of gene expression pathways associated with cell proliferation and differentiation and in particular in the regulation of CD38 expression (24, 25).
- preferred agents that downregulate CD38 expression according to the present invention include RAR antagonists, RXR antagonists and VDR antagonists or, alternatively, antagonists for reducing the capacity of the stem cells in responding to retinoic acid, retinoid and/or Vitamin D.
- antagonist refers to an agent that counteracts or abrogates the effects of an agonist or a natural ligand of a receptor. Further features relating to such antagonists are detailed hereinunder.
- Each of the agents described hereinabove may reduce the expression or activity of CD38 individually. However, the present invention aims to also encompas the use of any subcombination of these agents.
- protein agents e.g., antibodies
- protein agents of the present invention can be expressed from a polynucleotide encoding same and provided to ex-vivo cultured stem cells employing an appropriate gene delivery vehicle/method and a nucleic acid construct as is further described hereinunder.
- suitable constructs include, but are not limited to pcDNA3, pcDNA3.1 (+/-), pGL3, PzeoSV2 (+/-), pDisplay, pEF/myc/cyto, pCMV/myc/cyto each of which is commercially available from Invitrogen Co. (www.invitrogen.com).
- retroviral vector and packaging systems are those sold by Clontech, San Diego, Calif., including Retro-X vectors pLNCX and pLXSN, which permit cloning into multiple cloning sites and the transgene is transcribed from CMV promoter.
- Vectors derived from Mo-MuLV are also included such as pBabe, where the transgene will be transcribed from the 5'LTR promoter.
- the method of ex-vivo expanding a population of stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo is effected by modulating CD38 expression and/or activity, either at the protein level, using RAR, RXR or VDR antagonists or a CD38 inhibitor such as nicotinamide and analogs thereof, or at the at the expression level via genetic engineering techniques, as is detailed hereinabove, there are further provided, according to the present invention, several preferred methods of ex-vivo expanding a population of stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- a method of ex-vivo expanding a population of stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo is effected by providing the stem cells with ex-vivo culture conditions for ex-vivo cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding the population of stem cells while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- Reducing the capacity of the cells in responding to retinoic acid, retinoids and/or Vitamin D, or to retinoic acid, retinoid X and/or Vitamin D receptor signaling may be effected, for example, by the administration of chemical inhibitors, including receptor antagonists.
- the method of ex-vivo expanding a population of stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo is effected by providing the stem cells with ex-vivo culture conditions for ex-vivo cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor, retinoid-X receptor and/or Vitamin D receptor, thereby expanding the population of stem cells while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- Reducing the capacity of the cells to respond to retinoic acid, retinoid X and/or Vitamin D receptor signaling events includes treating the cells with antagonists supplied continuously or for a short-pulse period, and is effected by a diminution or abrogation of cellular signaling pathways through their respective, cognate receptors.
- Final concentrations of the antagonists may be, depending on the specific application, in the micromolar or millimolar ranges. For example, within about 0.1 ⁇ M to about 100 mM, preferably within about 4 ⁇ M to about 50 mM, more preferably within about 5 ⁇ M to about 40 mM.
- the method of ex-vivo expanding a population of stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo is effected by providing the stem cells with ex-vivo culture conditions for ex-vivo cell proliferation and with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding the population of stem cells while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo.
- Final concentrations of the nicotinamide or the analogs, derivatives or metabolites thereof are preferably, depending on the specific application, in the millimolar ranges. For example, within about 0.1 mM to about 20 mM, preferably within about 1 mM to about 10 mM, more preferably within about 5 mM to about 10 mM.
- ex-vivo expansion of populations of stem cells can be utilized for expanding a population of hematopoietic renewable stem cells ex-vivo.
- a method of ex-vivo expanding a population of hematopoietic renewable stem cells ex-vivo is effected by obtaining adult or neonatal umbilical cord whole white blood cells (also known in the art as mononuclear cell fraction) or whole bone marrow cells sample and providing the cells in the sample with ex-vivo culture conditions for stem cells ex-vivo cell proliferation and, at the same time, for reducing the expression and/or activity of CD38, as is described hereinabove, thereby expanding a population of a renewable stem cells in the sample.
- this method is effected by obtaining adult or neonatal umbilical cord whole white blood cells or whole bone marrow cells sample and providing the cells in the sample with ex-vivo culture conditions for stem cells ex-vivo cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding a population of a renewable stem cells in the sample.
- the method is effected by obtaining adult or neonatal umbilical cord whole white blood cells or whole bone marrow cells sample and providing the cells in the sample with ex-vivo culture conditions for stem cells ex-vivo cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor, thereby expanding a population of a renewable stem cells in the sample.
- the method is effected by obtaining adult or neonatal umbilical cord whole white blood cells or whole bone marrow cells sample and providing the cells in the sample with ex-vivo culture conditions for stem cells ex-vivo cell proliferation and with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding a population of a renewable stem cells in the sample.
- Expanding the population of stem cells can be further utilized, according to the present invention, in in vivo settings, such that according to still another aspect of the present invention there is provided a method of in-vivo expanding a population of stem cells, while at the same time, substantially inhibiting differentiation of the stem cells in-vivo.
- the method is effected by administering to a subject in need thereof a therapeutically effective amount of an agent, the agent serves for reducing an expression and/or activity of CD38, according to the features described hereinabove.
- the method is effected by administering to a subject in need thereof a therapeutically effective amount of an agent, which serves for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and or Vitamin D, as is defined hereinabove.
- the method is effected by administering to a subject in need thereof a therapeutically effective amount of an agent, which serves for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor, retinoid-X receptor and/or Vitamin D receptor, as is defined hereinabove.
- the method is effected by administering to a subject in need thereof a therapeutically effective amount of an agent selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite.
- an agent selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite.
- terapéuticaally effective amount refers to that amount of the agent being administered which will induce expansion of stem cells yet will limit the differentiation thereof.
- an ex-vivo expanded population of hematopoietic stem cells which comprises a plurality of cells characterized by 3-20 % of the cells being reselectable CD34 + cells, of which at least 40 % of cells are CD34 + dinl , i.e., fall below the median intensity in a FACS analysis, wherein, in the reselectable CD34 + cells, a majority of cells which are Lin ' are also CD34 + dim cells.
- the hematopoietic stem cells are derived from a source selected from the group consisting of bone marrow, peripheral blood and neonatal umbilical cord blood.
- the population of cells has a single genetic background.
- the ex-vivo expanded population of hematopoietic stem cells comprises at least N cells derived from a single donor, wherein N equals the average number of CD34 + cells derived from one sample of neonatal umbilical cord blood, bone marrow, or peripheral blood multiplied by 1,000.
- Cell surface expression of the CD34 and/or Lin markers can be determined, for example, via FACS analysis or immunohistological staining techniques.
- a self renewal potential of the stem cells can be determined in-vitro by long term colony formation (LTC-CFUc), as is further exemplified in the Examples section that follows, or by in-vivo engraftment in the SCID-Hu mouse model.
- the SCID-Hu mouse model employs C.B-17 scid/scid (SCID) mice transplanted with human fetal thymus and liver tissue or fetal BM tissue and provides an appropriate model for the evaluation of putative human hematopoietic stem cells.
- the model affords the proliferation of stem cells, in this case human hematopoietic stem cells to proliferate, and function in the hematopoietic microenvironment of human origin.
- Mice are typically irradiated, then delivered stem cells into the grafts, and reconstitution is measured by any number of methods, including FACS and immunohistochemistry of repopulated organs (Humeau L., et al Blood (1997) 90:3496).
- transplantable hematopoietic cell preparations which comprises an expanded population of hematopoietic stem cells propagated ex-vivo in the presence of an effective amount of an agent, which reduces the expression and/or activity of CD38, as described hereinabove, while at the same time, substantially inhibiting differentiation of the stem cells; and a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier or diluent such as sterile saline and aqueous buffer solutions.
- sterile saline and aqueous buffer solutions The use of such carriers and diluents is well known in the art.
- the transplantable hematopoietic cell preparation comprises an expanded population of hematopoietic stem cells propagated ex-vivo in the presence of an effective amount of an agent, which reduces a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, while at the same time, substantially inhibiting differentiation of the stem cells; and a pharmaceutically acceptable carrier.
- the transplantable hematopoietic cell preparation comprises an expanded population of hematopoietic stem cells propagated ex-vivo in the presence of an effective amount of an agent, which reduces a capacity of the stem cells in responding to retinoic acid receptor, retinoid X receptor and/or Vitamin D receptor signaling, while at the same time, substantially inhibiting differentiation of the stem cells; and a pharmaceutically acceptable carrier.
- the transplantable hematopoietic cell preparation comprises an expanded population of hematopoietic stem cells propagated ex-vivo in the presence of an effective amount of an agent selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite; and a pharmaceutically acceptable carrier.
- the ability of the agents of the present invention to inhibit differentiation of stem cells can be further used in various technical applications:
- the method is effected by handling the stem cell in at least one of the following steps: harvest, isolation and/or storage, in a presence of an effective amount of a retinoic acid receptor antagonist, a retinoid X receptor antagonist and/or a Vitamin D receptor antagonist.
- the method is effected by handling the stem cell in at least one of the following steps: harvest, isolation and/or storage, in a presence of an effective amount of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite.
- a cells collection/culturing bag is supplemented with an effective amount of a retinoic acid receptor antagonist, a retinoid X receptor antagonist and/or a Vitamin D receptor antagonist, which substantially inhibits cell differentiation.
- the cells collection/culturing bag of the present invention is supplemented with an effective amount of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite.
- a cells separation and/or washing buffer is supplemented with an effective amount of a retinoic acid receptor antagonist, a retinoid X receptor antagonist and/or Vitamin D receptor antagonists, which substantially inhibit cell differentiation and induce cell expansion.
- the separation and/or washing buffer is supplemented with an effective amount of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite.
- stem cells may serve to exert cellular gene therapy.
- Gene therapy refers to the transfer of genetic material (e.g., DNA or RNA) of interest into a host to freat or prevent a genetic or acquired disease or condition or phenotype.
- the genetic material of interest encodes a product (e.g., a protein, polypeptide, peptide, functional RNA, antisense) whose production in vivo is desired.
- the genetic material of interest can encode a hormone, receptor, enzyme, polypeptide or peptide of therapeutic value.
- ex-vivo gene therapy Two basic approaches to gene therapy have evolved: (i) ex-vivo or cellular gene therapy; and (ii) in vivo gene therapy.
- ex-vivo gene therapy cells are removed from a patient, and while being cultured are treated in-vitro.
- a functional replacement gene is introduced into the cells via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the host/patient.
- These genetically re-implanted cells have been shown to express the transfected genetic material in situ.
- the method is effected by (a) obtaining stem cells to be genetically modified; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing an expression and/or activity of CD38, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) genetically modifying the stem cells with the exogene. It is clear that the order of step (b) and (c) can be reversed.
- the method is effected by (a) obtaining stem cells to be genetically modified; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) genetically modifying the stem cells with the exogene.
- the method is effected by (a) obtaining stem cells to be genetically modified; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor and/or the retinoid X receptor and/or the Vitamin D receptor, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) genetically modifying the stem cells with the exogene.
- the method is effected by (a) obtaining stem cells to be genetically modified; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) genetically modifying the stem cells with the exogene.
- genetically modifying the cells is effected by a vector, which comprises the exogene or transgene, which vector is, for example, a viral vector or a nucleic acid vector.
- a vector which comprises the exogene or transgene
- which vector is, for example, a viral vector or a nucleic acid vector.
- viral vectors suitable for use in cellular gene therapy are known, examples are provided hereinbelow.
- nucleic acid vectors can be used to genetically transform the expanded cells of the invention, as is further described below.
- the expanded cells of the present invention can be modified to express a gene product.
- gene product refers to proteins, peptides and functional RNA molecules.
- the gene product encoded by the nucleic acid molecule is the desired gene product to be supplied to a subject. Examples of such gene products include proteins, peptides, glycoproteins and lipoproteins normally produced by an organ of the recipient subject.
- gene products which may be supplied by way of gene replacement to defective organs in the pancreas include insulin, amylase, protease, lipase, trypsinogen, chymotrypsinogen, carboxypeptidase, ribonuclease, deoxyribonuclease, triaclyglycerol lipase, phospholipase A2, elastase, and amylase; gene products normally produced by the liver include blood clotting factors such as blood clotting Factor VIII and Factor IX, UDP glucuronyl transferae, ornithine franscarbanoylase, and cytochrome p450 enzymes, and adenosine deaminase, for the processing of serum adenosine or the endocytosis of low density lipoproteins; gene products produced by the thymus include serum thymic factor, thymic humoral factor, thymopoiet
- the encoded gene product is one, which induces the expression of the desired gene product by the cell (e.g., the introduced genetic material encodes a transcription factor, which induces the transcription of the gene product to be supplied to the subject).
- the recombinant gene can provide a heterologous protein, e.g., not native to the cell in which it is expressed.
- a heterologous protein e.g., not native to the cell in which it is expressed.
- various human MHC components can be provided to non-human cells to support engraftment in a human recipient.
- the transgene is one, which inhibits the expression or action of a donor MHC gene product normally expressed in the micro-organ explant.
- a nucleic acid molecule introduced into a cell is in a form suitable for expression in the cell of the gene product encoded by the nucleic acid.
- the nucleic acid molecule includes coding and regulatory sequences required for transcription of a gene (or portion thereof) and, when the gene product is a protein or peptide, translation of the gene acid molecule include promoters, enhancers and polyadenylation signals, as well as sequences necessary for transport of an encoded protein or peptide, for example N-terminal signal sequences for transport of proteins or peptides to the surface of the cell or secretion.
- Nucleotide sequences which regulate expression of a gene product are selected based upon the type of cell in which the gene product is to be expressed and the desired level of expression of the gene product. For example, a promoter known to confer cell-type specific expression of a gene linked to the promoter can be used. A promoter specific for myoblast gene expression can be linked to a gene of interest to confer muscle-specific expression of that gene product. Muscle-specific regulatory elements, which are known in the art, include upstream regions from the dystrophin gene (Klamut et al., (1989) Mol. Cell Biol.9: 2396), the creatine kinase gene (Buskin and Hauschka, (1989) Mol. Cell Biol.
- Regulatory elements specific for other cell types are known in the art (e.g., the albumin enhancer for liver-specific expression; insulin regulatory elements for pancreatic islet cell-specific expression; various neural cell-specific regulatory elements, including neural dystrophin, neural enolase and A4 amyloid promoters).
- a regulatory element which can direct constitutive expression of a gene in a variety of different cell types, such as a viral regulatory element, can be used.
- viral promoters commonly used to drive gene expression include those derived from polyoma virus, Adenovirus 2, cytomegalovirus and Simian Virus 40, and retroviral LTRs.
- a regulatory element which provides inducible expression of a gene linked thereto, can be used.
- an inducible regulatory element e.g., an inducible promoter
- examples of potentially useful inducible regulatory systems for use in eukaryotic cells include hormone-regulated elements (e.g., see Mader, S. and White, J.H. (1993) Proc. Natl. Acad. Sci. USA 90: 5603-5607), synthetic ligand-regulated elements (see, e.g., Spencer, D.M. et al 1993) Science 262: 1019-1024) and ionizing radiation-regulated elements (e.g., see Manome, Y. Et al.
- tissue-specific or inducible regulatory systems which may be developed, can also be used in accordance with the invention.
- the nucleic acid is in the form of a naked nucleic acid molecule.
- the nucleic acid molecule introduced into a cell to be modified consists only of the nucleic acid encoding the gene product and the necessary regulatory elements.
- the nucleic acid encoding the gene product (including the necessary regulatory elements) is contained within a plasmid vector.
- plasmid expression vectors include CDM8 (Seed, B. (1987) Nature 329: 840) and pMT2PC (Kaufman, et al. (1987) EMBO J. 6: 187-195).
- the nucleic acid molecule to be introduced into a cell is contained within a viral vector.
- the nucleic acid encoding the gene product is inserted into the viral genome (or partial viral genome).
- the regulatory elements directing the expression of the gene product can be included with the nucleic acid inserted into the viral genome (i.e., linked to the gene inserted into the viral genome) or can be provided by the viral genome itself.
- Naked nucleic acids can be introduced into cells using calcium-phosphate mediated transfection, DEAE-dextran mediated transfection, electroporation, liposome-mediated transfection, direct injection, and receptor-mediated uptake.
- Naked nucleic acid e.g., DNA
- a precipitate containing the nucleic acid and calcium phosphate For example, a HEPES-buffered saline solution can be mixed with a solution containing calcium chloride and nucleic acid to form a precipitate and the precipitate is then incubated with cells.
- a glycerol or dimethyl sulfoxide shock step can be added to increase the amount of nucleic acid taken up by certain cells.
- CaPO4-mediated transfection can be used to stably (or transiently) transfect cells and is only applicable to in vitro modification of cells.
- nucleic acid can be introduced into cells by forming a mixture of the nucleic acid and DEAE-dextran and incubating the mixture with the cells.
- a dimethylsulfoxide or chloroquine shock step can be added to increase the amount of nucleic acid uptake.
- DEAE-dextran transfection is only applicable to in vitro modification of cells and can be used to introduce DNA transiently into cells but is not preferred for creating stably transfected cells. Thus, this method can be used for short-term production of a gene product but is not a method of choice for long-term production of a gene product. Protocols for DEAE-dextran-mediated transfection can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al. (eds.) Greene Publishing Associates (1989), Section 9.2 and in Molecular Cloning: A Laboratory Manual, 2nd Edition, Sambrook et al. Cold Spring Harbor Laboratory Press, (1989), Sections 16.41-16.46 or other standard laboratory manuals.
- Naked nucleic acid can also be introduced into cells by incubating the cells and the nucleic acid together in an appropriate buffer and subjecting the cells to a high- voltage electric pulse.
- the efficiency with which nucleic acid is introduced into cells by electroporation is influenced by the strength of the applied field, the length of the electric pulse, the temperature, the conformation and concentration of the DNA and the ionic composition of the media. Electroporation can be used to stably (or transiently) transfect a wide variety of cell types and is only applicable to in vitro modification of cells. Protocols for electroporating cells can be found in Current Protocols in Molecular Biology, Ausubel F.M. et al. (eds.) Greene Publishing Associates, (1989), Section 9.3 and in Molecular Cloning: A Laboratory Manual, 2nd Edition, Sambrook et al. Cold Spring Harbor Laboratory Press, (1989), Sections 16.54-16.55 or other standard laboratory manuals.
- liposome-mediated transfection Another method by which naked nucleic acid can be introduced into cells includes liposome-mediated transfection (lipofection).
- the nucleic acid is mixed with a liposome suspension containing cationic lipids.
- the DNA/liposome complex is then incubated with cells.
- Liposome mediated transfection can be used to stably (or transiently) transfect cells in culture in vitro. Protocols can be found in Current Protocols in Molecular Biology, Ausubel F.M. et al. (eds.) Greene Publishing Associates, (1989), Section 9.4 and other standard laboratory manuals. Additionally, gene delivery in vivo has been accomplished using liposomes. See for example Nicolau et al. (1987) Meth. Enz.
- Naked nucleic acid can also be introduced into cells by directly injecting the nucleic acid into the cells.
- DNA can be introduced by microinjection. Since each cell is microinjected individually, this approach is very labor intensive when modifying large numbers of cells.
- microinjection is a method of choice is in the production of transgenic animals (discussed in greater detail below).
- the DNA is stably introduced into a fertilized oocyte, which is then allowed to develop into an animal.
- the resultant animal contains cells carrying the DNA introduced into the oocyte.
- Direct injection has also been used to introduce naked DNA into cells in vivo (see e.g., Acsadi et al.
- a delivery apparatus e.g., a "gene gun" for injecting DNA into cells in vivo can be used.
- a delivery apparatus e.g., a "gene gun”
- Such an apparatus is commercially available (e.g., from BioRad).
- Naked nucleic acid can be complexed to a cation, such as polylysine, which is coupled to a ligand for a cell-surface receptor to be taken up by receptor-mediated endocytosis (see for example Wu, G. and Wu, CH. (1988) J. Biol. Chem. 263: 14621; Wilson et al. (1992) J. Biol. Chem. 267: 963-967; and U.S. Patent No. 5,166,320). Binding of the nucleic acid-ligand complex to the receptor facilitates uptake of the DNA by receptor-mediated endocytosis.
- Receptors to which a DNA-ligand complex has targeted include the transferrin receptor and the asialoglycoprotein receptor.
- a DNA-ligand complex linked to adenovirus capsids which naturally disrupt endosomes, thereby releasing material into the cytoplasm can be used to avoid degradation of the complex by intracellular lysosomes (see for example Curiel et al. (1991) Proc. Natl. Acad. Sci. USA 88: 8850; Cristiano et al. (1993) Proc. Natl. Acad. Sci. USA 90: 2122-2126).
- Receptor-mediated DNA uptake can be used to introduce DNA into cells either in vitro or in vivo and, additionally, has the added feature that DNA can be selectively targeted to a particular cell type by use of a ligand which binds to a receptor selectively expressed on a target cell of interest.
- telomeres when naked DNA is introduced into cells in culture (e.g., by one of the transfection techniques described above, only a small fraction of cells (about 1 out of 10 ) typically integrate the transfected DNA into their genomes (i.e., the DNA is maintained in the cell episomally).
- a selectable marker in order to identify cells, which have taken up exogenous DNA, it is advantageous to transfect nucleic acid encoding a selectable marker into the cell along with the nucleic acid(s) of interest.
- selectable markers include those, which confer resistance to drugs such as G418, hygromycin and methotrexate. Selectable markers may be introduced on the same plasmid as the gene(s) of interest or may be introduced on a separate plasmid.
- a preferred approach for introducing nucleic acid encoding a gene product into a cell is by use of a viral vector containing nucleic acid, e.g., a cDNA, encoding the gene product.
- a viral vector containing nucleic acid e.g., a cDNA
- Infection of cells with a viral vector has the advantage that a large proportion of cells receive the nucleic acid which can obviate the need for selection of cells which have received the nucleic acid.
- molecules encoded within the viral vector e.g., a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid and viral vector systems can be used either in vitro or in vivo.
- Defective retroviruses are well characterized for use in gene transfer for gene therapy pu ⁇ oses (for review see Miller, A.D. (1990) Blood 76: 271).
- a recombinant retrovirus can be constructed having a nucleic acid encoding a gene product of interest inserted into the retroviral genome. Additionally, portions of the retroviral genome can be removed to render the retrovirus replication defective. The replication defective retrovirus is then packaged into virions, which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al.
- retroviruses include pLJ, pZIP, pWE and pEM, which are well known to those skilled in the art.
- suitable packaging virus lines include ⁇ Crip, ⁇ Crip, ⁇ 2 and ⁇ Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and or in vivo (see for example Eglitis, et al. (1985) Science 230: 1395-1398; Danosand Mulligan (1988) Proc.
- Retroviral vectors require target cell division in order for the retroviral genome (and foreign nucleic acid inserted into it) to be integrated into the host genome to stably introduce nucleic acid into the cell. Thus, it may be necessary to stimulate replication of the target cell.
- adenovirus The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner et al. (1988) BioTechniques 6:616; Rosenfeld et al. (1991) Science 252:431-434; and Rosenfeld et al. (1992) Cell 68: 143-155.
- Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus are well known to those skilled in the art.
- Recombinant adenoviruses are advantageous in that they do not require dividing cells to be effective gene delivery vehicles and can be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld et al. (1992) cited supra), endothelial cells (Lemarchand et al. (1992) Proc. Natl. Acad. Sci. USA 89: 6482-6486), hepatocytes (Herz and Gerard (1993) Proc. Natl. Acad. Sci. USA 90: 2812-2816) and muscle cells (Quantin et al. (1992) Proc. Natl. Acad. Sci. USA 89: 2581-2584).
- introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA).
- the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al. cited supra; Haj-Ahmand and Graham (1986) J. Virol 57: 267).
- Most replication-defective adenoviral vectors currently in use are deleted for all or parts of the viral El and E3 genes but retain as much as 80% of the adenoviral genetic material.
- Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a he ⁇ es virus, as a helper virus for efficient replication and a productive life cycle.
- another virus such as an adenovirus or a he ⁇ es virus
- helper virus for efficient replication and a productive life cycle.
- AAV Adeno-associated virus
- It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al. (1992) Am. J. Respir. Cell. Mol. Biol. 7: 349-356; Samulski et al. (1989) J. Virol.
- AAV vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5: 3251-3260 can be used to introduce DNA into cells.
- a variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al. (1984) Proc. Natl. Acad. Sci. USA 81 : 6466-6470; Tratschin et al. (1985) Mol. Cell Biol.
- DNA introduced into a cell can be detected by a filter hybridization technique (e.g., Southern blotting) and RNA produced by transcription of introduced DNA can be detected, for example, by Northern blotting, RNase protection or reverse transcriptase-polymerase chain reaction (RT-PCR).
- RNA produced by transcription of introduced DNA can be detected, for example, by Northern blotting, RNase protection or reverse transcriptase-polymerase chain reaction (RT-PCR).
- RT-PCR reverse transcriptase-polymerase chain reaction
- the gene product can be detected by an appropriate assay, for example by immunological detection of a produced protein, such as with a specific antibody, or by a functional assay to detect a functional activity of the gene product, such as an enzymatic assay.
- an expression system can first be optimized using a reporter gene linked to the regulatory elements and vector to be used.
- the reporter gene encodes a gene product, which is easily detectable and, thus, can be used to evaluate efficacy of the system.
- Standard reporter genes used in the art include genes encoding ⁇ -galactosidase, chloramphenicol acetyl transferase, luciferase and human growth hormone.
- the modified population of cells may be used without further isolation or subcloning of individual cells within the population. That is, there may be sufficient production of the gene product by the population of cells such that no further cell isolation is needed.
- Such a population of uniform cells can be prepared by isolating a single modified cell by limiting dilution cloning followed by expanding the single cell in culture into a clonal population of cells by standard techniques.
- ex-vivo expansion of stem cells can be advantageously utilized in hematopoietic cells transplantation or implantation.
- a method of hematopoietic cells transplantation or implantation is effected by (a) obtaining hematopoietic stem cells to be transplanted from a donor; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing an expression and/or activity of CD38, thereby expanding the population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) transplanting or implanting the stem cells to a recipient.
- the method is effected by (a) obtaining hematopoietic stem cells to be transplanted from a donor; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding the population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) transplanting or implanting the stem cells to a recipient.
- the method is effected by (a) obtaining hematopoietic stem cells to be transplanted from a donor; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor, thereby expanding the population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) transplanting or implanting the stem cells to a recipient.
- the method is effected by (a) obtaining hematopoietic stem cells to be transplanted from a donor; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding the population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells ex-vivo; and (c) transplanting or implanting the stem cells to a recipient.
- the donor and the recipient can be a single individual or different individuals, for example, allogeneic individuals.
- allogeneic transplantation is practiced, regimes for reducing implant rejection and/or graft vs. host disease, as well know in the art, should be undertaken. Such regimes are currently practiced in human therapy. Most advanced regimes are disclosed in publications by Slavin S. et al., e.g., J Clin Immunol (2002) 22: 64, and J Hematother Stem Cell Res (2002) 11: 265), Gur H. et al. (Blood (2002) 99: 4174), and Martelli MF et al, (Semin Hematol (2002) 39: 48), which are inco ⁇ orated herein by reference.
- a method of adoptive immunotherapy is effected by (a) obtaining hematopoietic stem cells from a recipient; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing an expression and/or activity of CD38, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (c) transplanting the stem cells to the recipient.
- the method is effected by (a) obtaining hematopoietic stem cells from a recipient; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (c) transplanting the stem cells to the recipient.
- the method is effected by (a) obtaining hematopoietic stem cells from a recipient; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and, at the same time, for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor and/or the retinoid X receptor and/or the Vitamin D receptor, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (c) transplanting the stem cells to the recipient.
- the method is effected by (a) obtaining hematopoietic stem cells from a recipient; (b) providing the stem cells with ex-vivo culture conditions for cell proliferation and with nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (c) transplanting the stem cells to the recipient.
- the effect of the agents that reduce CD38 expression or activity used in context of the present invention is not limited to ex-vivo settings. Hence, based o the findings herein described, novel in-vivo applications for these agents are envisaged.
- a method of mobilization of bone marrow stem cells into the peripheral blood of a donor for harvesting the cells is effected by (a) administering an effective amount of an agent to the donor for reducing the expression and/or activity of CD38, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (b) harvesting the cells by leukophoresis.
- the method is effected by (a) administering an effective amount of an agent to the donor for reducing a capacity of the stem cells in responding to retinoic acid, retinoids and/or Vitamin D, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (b) harvesting the cells by leukophoresis.
- the method is effected by (a) administering an effective amount of an agent to the donor for reducing a capacity of the stem cells in responding to signaling pathways involving the retinoic acid receptor and/or the retinoid X receptor and/or the Vitamin D receptor, thereby expanding a population of the stem cells,
- the method is effected by (a) administering to the donor an effective amount of an agent selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite, thereby expanding a population of the stem cells, while at the same time, substantially inhibiting differentiation of the stem cells; and (b) harvesting the cells by leukophoresis.
- an agent selected from the group consisting of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite
- the methods of mobilization of stem cells further comprise administering to the donor at least one cytokine, preferably at least one early cytokine, which are presently used to induce cell mobilization into peripheral blood.
- at least one cytokine preferably at least one early cytokine, which are presently used to induce cell mobilization into peripheral blood.
- a method of decelerating maturation/differentiation of erythroid precursor cells for the treatment of ⁇ -hemoglobinopathic patients is effected by administering to the patient an agent for reducing the expression and/or activity of CD38, thereby expanding a population of erythroid precursor cells, while at the same time, substantially inhibiting differentiation of the erythroid precursor cells, such that upon natural removal of the agent from the body, the cells undergo accelerated maturation, resulting in elevated production of fetal hemoglobin.
- the agent used according to this method of the present invention can be an agent for abrogating or reducing a capacity of the cells in responding to retinoic acid, retinoids and or Vitamin D, an agent for abrogating or reducing a capacity of the cells in responding to retinoic acid, retinoid X and/or Vitamin D receptor signaling or an agent such as nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative and a nicotinamide or a nicotinamide analog metabolite.
- administration of the agents the reduce CD38 expression or activity may be by a pharmaceutical composition including same, which may further include thickeners, carriers, buffers, diluents, surface active agents, preservatives, and the like, all as well known in the art.
- the pharmaceutical composition may be administered in various ways, depending on the preference for local or systemic treatment, and on the area to be treated.
- Administration may be done topically (including opthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip or intraperitoneal, subcutaneous, subdural, intramuscular or intravenous injection, or via an implantable delivery device.
- Formulations for topical administration may include, but are not limited to, lotions, ointments, gels, creams, suppositories, drops, liquids, sprays and powders.
- Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.
- Formulations for parenteral administration may include, but are not limited to, sterile solutions, which may also contain buffers, diluents and other suitable additives.
- Formulations for implantable delivery devices may similarly include, but are not limited to, sterile solutions, which may also contain buffers, diluents and other suitable additives.
- Dosing is dependent on responsiveness of the condition for treatment, but will normally be one or more doses per day, with course of treatment lasting from several days to several months or until a required effect is achieved. Persons ordinarily skilled in the art can easily determine optimum dosages, dosing methodologies and repetition rates. Slow release administration regimes may be advantageous in some applications.
- providing the stem cells with the conditions for ex-vivo cell proliferation comprises providing the cells with nutrients and with cytokines.
- the cytokines are early acting cytokines, such as, but not limited to, stem cell factor, FLT3 ligand, interleukin- 1, interleukin-2, interleukin-3, interleukin-6, interleukin- 10, interleukin-12, tumor necrosis factor- ⁇ and thrombopoietin. It will be appreciated in this respect that novel cytokines are continuously discovered, some of which may find uses in the methods of cell expansion of the present invention.
- Late acting cytokines can also be used. These include, for example, granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, erythropoietin, FGF, EGF, NGF, VEGF, LIF, Hepatocyte growth factor and macrophage colony stimulating factor.
- the stem cells to be expanded by the method of the present invention can be embryonic stem cells or adult stem cells.
- Embryonic stem cells and methods of their retrieval are well known in the art and are described, for example, in Trounson AO (Reprod Fertil Dev (2001) 13: 523), Roach ML (Methods Mol Biol (2002) 185: 1), and Smith AG (Annu Rev Cell Dev Biol (2001) 17:435).
- Adult stem cells are stem cells, which are derived from tissues of adults and are also well known in the art. Methods of isolating or enriching for adult stem cells are described in, for example, Miraglia, S. et al. (1997) Blood 90: 5013, Uchida, N. et al. (2000) Proc. Natl. Acad. Sci. USA 97: 14720, Simmons, P.J.
- the stem cells are hematopoietic stem cells.
- Such stem cells can be derived from bone marrow, peripheral blood and neonatal umbilical cord blood.
- Methods of enriching white blood cells (mononuclear cells) for stem cells are well known in the art, including, selecting for CD34 + expressing cells.
- CD34 + cells include pluripotent stem cells and very early progenitor cells, which, under the appropriate conditions may revert to stem cells, as they are not committed cells.
- stem cells present in the mononuclear cell fraction of blood i.e., white blood cells
- the stem cells that undergo expansion are mixed (e.g., not separated from, not enriched) with committed cells.
- This embodiment of the present invention is of particular advantage because it relieves the tedious need for cell separation prior to ex-vivo culturing the cells.
- the cells are enriched for hematopoietic CD34 + cells and are characterized by an absence, or significantly diminished expression of cell surface antigens CD38 and Lineage specific antigens (Lin, including: CD3, CD61, CD19, CD33, CD14, CD15 and/or CD4).
- trans-differentiation refers to differentiation of adult stem cells into a tissue from which they were derived.
- differentiation of CD34 + hematopoietic cells to different committed/mature blood cells constitutes cis-differentiation.
- trans-differentiation refers to differentiation of adult stem cells into a tissue from which they were not derived.
- the differentiation of CD34 + hematopoietic cells to cells of different tissue origin, e.g., myocites constitutes trans-differentiation.
- the stem cells used for cell expansion in context of the present invention can be obtained from any tissue of any multicellular organism including both animals and plants.
- Stem cells were shown to exist in many organs and tissues and are believed to exist in all tissues of animals, including, but not limited to, bone marrow (Rowley SD et al (1998) Bone Ma ⁇ ow Transplant 21 : 1253), peripheral blood (Koizumi K, (2000) Bone Marrow Transplant 26: 787, liver (Petersen BE et al (1998) Hepatology 27: 433) and brain (Pagano SF et al (2000) Stem Cells 18: 295). It is anticipated that all such cells are expandable using the methods of the present invention.
- Reducing the capacity of the stem cells in responding to the above antagonists and/or signaling pathways of the above receptors is by ex-vivo culturing the stem cells in a presence of an effective amount of at least one retinoic acid receptor antagonist, at least one retinoid X receptor antagonist and/or at least one Vitamin D receptor antagonist, preferably, for a time period of 0.1-50 %, preferably, 0.1-25 %, more preferably, 0.1-15 %, of an entire ex-vivo culturing period of the stem cells or for the entire period.
- an initial pulse exposure to an antagonist is sufficient to exert cell expansion long after the antagonist was removed from the culturing set up.
- retinoic acid receptor antagonist used in context of the different aspects and embodiments of the present invention can be:
- LGN 100572 l-(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)ethanone, l-(3-propoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)ethanone,
- Vitamin D receptor antagonist used in context of the different aspects and embodiments of the present invention can be: 1 alpha, 25-(OH)-D3-26,23 lactone; 1 alpha, 25-dihydroxyvitamin D (3); the 25-carboxylic ester ZK159222; (23S)- 25-dehydro-l alpha-OH-D (3); (23R)-25-dehydro-l alpha-OH-D (3); 1 beta, 25 (OH) 2 D 3 ; 1 beta, 25(OH) 2 -3-epi-D 3 ; (23S) 25-dehydro-l alpha(OH) D3-26,23-lactone; (23R) 25-dehydro-l al ⁇ ha(OH)D3-26,23-lactone and
- the above listed antagonists are known for their high affinity towards their respective cognate receptors. However, it may be possible for these molecules to be active towards other receptors.
- an assay of determining whether a specific retinoic acid receptor antagonist, a retinoid X receptor antagonist or a Vitamin D receptor antagonist is an effective cell expansion agent comprises culturing a population of stem cells, e.g., CD34 hematopoietic cells, or cells of a substantially non-differentiated cell line, such as, but not limited to, USP-1 and USP-3 (Sukoyan MA (2002) Braz J Med Biol Res, 35(5):535, C6, c2, Cr/A-3, DBl and B6-26 (US Patent No. 6,190,910), and H9.1 and H9.2 (Odorico J. S.
- stem cells e.g., CD34 hematopoietic cells
- a substantially non-differentiated cell line such as, but not limited to, USP-1 and USP-3 (Sukoyan MA (2002) Braz J Med Biol Res, 35(5):535, C6, c2, Cr/A-3, DBl and B6-26 (US
- culturing the population of stem cells or cells of a substantially non-differentiated cell line is performed in a presence of an effective amount of a cytokine, preferably, an early acting cytokine or a combination of such cytokines, e.g., thrombopoietin (TPO), interleukin-6 (IL-6), an FLT-3 ligand and stem cell factor (SCF).
- a cytokine preferably, an early acting cytokine or a combination of such cytokines, e.g., thrombopoietin (TPO), interleukin-6 (IL-6), an FLT-3 ligand and stem cell factor (SCF).
- TPO thrombopoietin
- IL-6 interleukin-6
- SCF stem cell factor
- RAR retinoic acid receptor antagonist
- the RAR antagonist AGN 194310 was synthesized according to the procedure described by Johnson (26), with some modification.
- the organic layer was washed with IM aqueous HCI (50 ml), 5 % aqueous NaOH (50 ml) and a saturated solution of NaCl (50 ml) and was thereafter dried over magnesium sulfate.
- Trifluoromethanesulfonic anhydride was added to a stirred solution of 6-hydroxy-2,2-dimethyl-thiochroman-4-one in anhydrous pyridine. The mixture was sti ⁇ ed for 4 hours at 0 °C, then stirred overnight at room temperature. Concentration under high vacuum yielded a residue that was treated with diethyl ether (75 ml). The ether solution was separated from the precipitate resulting from the formation of a salt between pyridine and trifluoromethanesulfonic acid. The ether solution was washed with water, then aqueous NaCl, and dried over MgSO 4 . After removing the ether, the residue was crystallized. Traces of pyridine were removed under high vacuum.
- the crude product (1.74 gram) was purified by column chromatography with 35 grams silica, and 2 % ethyl acetate/petroleum ether (500ml, 20 x 25 ml) eluent system. After evaporation of the combined eluted product fractions, ethyl 4-[(2,2-dimethyl-4-trifluoromethanesulfonyloxy)-(2H)- thiochromen-6-yl) ethynyl] benzoate (1.16 gram, 71 % yield, m.p. 100-104 °C) was obtained, as a pale yellow solid.
- [2H]-thiochromen-6-yl]-ethynyl]-benzoate 7.25 ml of 1.7 M LiC(CH 3 ) 3 in pentane were added to a solution of p-bromo-ethyl-benzene (cooled to - 78 °C) in 4 ml of THF.
- Mononuclear cell fraction collection and purification Human blood cells were obtained from umbilical cord blood from female patients following full-term, normal delivery (informed consent was obtained). Samples were collected and processed within 12 hours postpartum. Blood was mixed with 3 % Gelatin (Sigma, St. Louis, MO), sedimented for 30 minutes to remove most red blood cells. The leukocyte-rich fraction was harvested and layered on a Ficoll-Hypaque gradient (1.077 gram/ml; Sigma), and centrifuged at 400 g for 30 minutes.
- PBS phosphate-buffered saline
- BSA bovine serum albumin
- CD34 + mononuclear cells To purify CD34 + mononuclear cells, the fraction was subjected to two cycles of immuno-magnetic separation using the MiniMACS or Clinimax CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Auburn, CA) as per manufacturer's recommendations. The purity of the CD34 population obtained ranged from 95 % to 98 % as was determined by flow cytometry (see below).
- the purified CD34 + cells were further labeled for CD38 (Dako A/S, Glostrup, Denmark) or lineage antigens (BD Biosciences, Erermbodegem, Belgium). The negatively labeled fraction was measured and sorted by a FACS sorter.
- CD34 " Lin” purification the CD34 " fraction was depleted from cells expressing lineage antigens using a negative selection column (StemCell Technologies, Vancouver, BC, Canada).
- CD34 +/ ⁇ cell populations were cultured in 24-well Costar
- TPO Thrombopoietin
- IL-6 interleukin-6
- SCF stem cell factor
- FGF FGF
- EGF EGF
- NGF NGF
- VEGF vascular endothelial growth factor
- LIF Hepatocyte growth factor
- MNC mononuclear fraction cells
- CD34 + purified and whole MNC cultures were prepared and maintained as described above.
- AGN 194310 RAR antagonist was added to test cultures at concentrations ranging from 1 x IO "3 - 1 x 10 " ⁇ M [or 410 ⁇ g/1 to 4.1 x IO "5 ⁇ g/1] .
- the antagonist was added for a predetermined, limited period, for up to three weeks or continuously during the entire culture period.
- Cells were harvested, washed with a PBS solution containing 1 % bovine sera albumin (BSA) and 0.1 % sodium azide (Sigma), and stained at 4 °C for 60 minutes with fluorescein isothiocyanate or phycoerythrin-conjugated antibodies (all from Immunoquality Products, the Netherlands). The cells were then washed with the same buffer and analyzed by FACS caliber or Facsta ⁇ lus flow cytometers. Cells were passed at a rate of 1000 cells/second, using saline as the sheath fluid. A 488 nm argon laser beam served as the light source for excitation. Emission of ten thousand cells was measured using logarithmic amplification, and analyzed using CellQuest software.
- BSA bovine sera albumin
- Sigma sodium azide
- CD34 surface expression on short and long-term cultures initiated either with purified CD34 + cells or the entire MNC fraction was determined as follows: CD34 + cells were positively reselected (Miltenyi kit) and counted. Purity was confirmed by subsequent FACS and cell mo ⁇ hology analysis. Reselected CD34 + cell subsets were stained for the following combination of antigens: CD34PE/CD38FITC and CD34PE/38, 33, 14, 15, 3, 4, 61, 19 (Lin) FITC. The fraction positive for CD34 and negative for CD38 was defined as CD34 + CD38 ⁇ The fraction positive for CD34 and negative for LIN was defined as CD34 + Lin * cell fraction. Cell population calculations:
- FACS analysis results are given as percentage values of cells. Absolute numbers of subsets are calculated from the absolute number of CD34 + cells.
- CD34 + /CD38- and CD34 + /Lin " cells were purified from 3 thawed cord blood units and stained for the above markers. The mean of these experiments was considered as the baseline value.
- Total cell counts, numbers of CD34 + cells and subsets, and CFU numbers are presented as cumulative numbers, with the assumption that the cultures had not been passaged; i.e., the number of cells per ml were multiplied by the number of passages performed.
- CFU Colony Forming Unit
- CD34 + cell enriched cultures were initiated in the presence of a combination of 4 cytokines with and without different concentrations of the retinoic acid receptor antagonist AGN 194310. Two weeks after the initial seeding, the percentage of cells bearing the CD34 + marker (considered to be mostly committed progenitor cells), as well as the percentage of cells bearing the markers CD34 + /CD38 " and CD34 + Lin " (considered to represent the stem and early progenitor compartment) was ascertained by FACS analysis.
- Retinoic acid receptor (RAR) antagonist treated cultures contained similar numbers of total and CD34 + cells as compared to cytokine-only treated cultures.
- RAR antagonist treatment completely abolished the expression of the CD38 antigen and concu ⁇ ently, significantly inhibited the expression of the additional differentiation associated antigens CD33, CD14, CDI 5, CD4, CD3, CD19 and CD61, which was a totally unexpected phenomenon.
- Table 1 summarizes the data from the FACS analysis. Table 1
- the stem and early progenitor cell subsets were measured following 2 weeks expansion from a re-selected CD34 + cell fraction.
- CD34 + cells were re-selected and analyzed by FACS, as above, for the presence of the surface markers CD34 + CD38 " and CD34 + Lin " ( Figure 2).
- RAR antagonist-treated cultures of reselected CD34 + cells revealed a 1000-fold increase in CD34 + CD38 " and a 500-fold increase in CD34 + Lin " surface expression.
- reselected control cultures treated with cytokines alone revealed only a 36-fold expansion of the CD34 + CD38 " and an 8-fold expansion of the CD34 + Lin " compartments.
- RAR antagonists preferably enable marked proliferation, yet limited differentiation of the stem cell compartment. RAR antagonists thus directly impact the high fold expansion of these rare cells during the short-term culture period. It could also be concluded that the antagonists do not have any positive or negative effect on more mature, committed CD34 + cells. RAR antagonist treatment of enriched CD34 + populations alters surface differentiation marker expression resulting in large numbers of cells with a less-differentiated phenotype in long-term cultures:
- CD34 + CD38 ' and CD34 + Lin " surface markers was verified in a highly purified, CD34+ re-selected fraction ( Figure 3B-C). After two weeks in culture, while control samples revealed a modest 10-fold increase in CD34 Lin * surface expression, RAR antagonist treated cultures expanded by a marked 530-fold. CD34 + Lin " expression at week eleven, 9 weeks after the termination of the treatment with the antagonist, revealed a 16,700- fold increase in CD34 + Lin " expression. Comparison between the fold-expansion of RAR antagonist treated cultures versus that of control cells indicates that only the former enables a significant continuous proliferation of stem cells in extended long-term cultures. The continued expansion of stem cells in the absence of RAR antagonists indicates that even a relatively short pulse with the antagonist is sufficient to modify stem cell responses.
- FIG. 5 A representative FACS chart plot of CD34 + cells 2 and 11 weeks following re-selection is shown in Figure 5. While control cultures expressed markers for a more differentiated state, RAR antagonist treated samples expressed a less differentiated phenotype, as evidenced by the leftward shift in expression profile. These findings indicated that although not lineage negative, most of the CD34 + cells derived from RAR antagonist treated cultures expressed fewer lineage related surface markers.
- RAR antagonist treatment of mononuclear cell populations expands a population of cells with a less-differentiated phenotype
- Mononuclear cell fractions cultured in the presence of RAR antagonists and cytokines similarly revealed a significant increase in the number of CD34+Lin- cells (78 %, 24 %) as quantitated by FACS analysis from a reselected, highly purified CD34+ cell fraction, as compared to controls, 2 and 5 weeks (respectively), after initial seeding (Table 3).
- RAR antagonists and cytokines similarly revealed a significant increase in the number of CD34+Lin- cells (78 %, 24 %) as quantitated by FACS analysis from a reselected, highly purified CD34+ cell fraction, as compared to controls, 2 and 5 weeks (respectively), after initial seeding (Table 3).
- most remarkable is that these cells responded to the RAR antagonists and expanded an undifferentiated population, even in mixed culture conditions, without prior purification of the CD34 + population.
- RAR antagonist treatment was sufficient to stimulate specific expansion of the stem/progenitor cell compartment, as 5 weeks post seeding, while control MNCs had no detectable CD34 + population, RAR antagonist treated cultures revealed significant numbers of CD34 + cells, and those that were lineage marker deficient. Thus, any factors elaborated by the MNC culture cells that suppress CD34 + cell survival in control samples are insufficient to override the signal provided by the RAR antagonist to elaborate this compartment. Table 3
- RAR antagonist treatment enhances long-term culture colony forming unit (LTC-CFUc) ability
- CFUs colony forming units
- RAR antagonist treatment enhances extended long-term culture colony forming unit (LTC-CFUc) ability:
- DMEM (Beit Haemek, Israel), incubated with DMEM in the presence 0.05% collagenase for 30 minutes at 37 ° C, ground and passed through a 200 ⁇ m mesh sieve, yielding individual hepatocytes. Cells were washed twice and viability was ascertained with trypan blue. Cells were plated in collagen-coated, 35 mm tissue culture plates at a density of 4-x 10 live cells/ml in F12 media (containing 15 mM Hepes, 0.1% glucose, 10 mM sodium bicarbonate, lOOunits/ml penicillin-streptomycin, glutamine, 0.5 units/ml insulin, 7.5m eg/ml hydrocortisone, and 10% fetal bovine serum). Medium was changed after 12 hours, the cells were washed twice with phosphate buffered saline (PBS) and new medium was added. Medium was changed twice a week.
- PBS phosphate buffered saline
- Hepatocytes were also grown in the presence of Epidermal Growth Factor (EGF),Platelet-Derived Growth Factor ⁇ chain (PDGF-BB),Fibroblast growth Factors (FGF-4) and Hepatocyte Growth Factor (HGF), at 20-50 ng/ml each, for the entire culturing period according to the method of Schwartz et al. (Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest. 2002; 109 (10): 1291-302).
- EGF Epidermal Growth Factor
- PDGF-BB Platelet-Derived Growth Factor ⁇ chain
- FGF-4 Fibroblast growth Factors
- HGF Hepatocyte Growth Factor
- Hepatocytes were also grown in serum free medium according to the method of Runge et al. (Runge D, Runge DM, Jager D, Lubecki KA, Beer Stolz D, Karathanasis S, Kietzmann T, Strom SC, Jungermann K, Fleig WE, Michalopoulos GK.Serum-free, long-term cultures of human hepatocytes: maintenance of cell mo ⁇ hology, transcription factors, and liver-specific functions. Biochem Biophys Res Commun. 2000; 269(1): 46-53).
- cells are grown in the presence or absence of the retinoic acid antagonist AGN 194310 at concentrations ranging from IO "5 M to 10 ⁇ 9 M.
- cultures treated with 10 "5 M antagonist were detached with 0.25% trypsin, split and replated at a 1:2 ratio.
- the cells were either immunostained as described below, or visualized with Giemsa staining.
- Murine hepatocyte cultures supplemented with EGF and HGF were evaluated as primary cultures, or following first and second passages.
- First passage cultures were grown for 2 weeks, split 1 :2 and immunostained 8 days later for the presence of albumin, as described below.
- Second passage cultures were similarly grown for 2 weeks, split 1:2, and grown for an additional week, then split 1 :4 and similarly immunostained 4 days later.
- Hepatocytes and ex-vivo expanded cells were fixed in methanol directly in their cell culture plates and each procedure performed by standard procedures as outlined below.
- ICG insulin receptor gamma-N-(ICG) dye uptake.
- ICG (Sigma, Jerusalem, Israel)) was dissolved in DMEM yielding a final concentration of 1 mg/ml (Yamada T, Yoshikawa M, Kanda S,
- Ex-vivo expanded cells and hepatocytes were stained with Giemsa stain, according to manufacturer's instructions (Shandon, Pittsburg, PA) for 4 minutes at room temperature, washed in buffer solution for 4 minutes and washed 3-4 times with rinse solution.
- Hepatocytes were probed for expression of ⁇ -fetoprotein (AFP) using a rabbit polyclonal antibody raised against a recombinant protein of human origin that cross-reacts with AFP from mouse (H-l 40 Santa Cruz Technology, Santa Cruz, CA), and albumin using a rabbit antiserum to mouse albumin
- AFP ⁇ -fetoprotein
- Samples were then visualized for peroxidase activity (via methods according to manufacturer's instructions using the Envision HRP-system (Dako, Ca ⁇ interia, CA), and counterstained with hematoxylin (Dako, Ca ⁇ interia, CA).
- hepatocyte stem progenitor cells are defined as oval cells
- Figure 9A Hepatocytes cultures grown in the presence of the antagonist and in the absence of cytokines for 3 weeks were trypsinized, split, and replated.
- Second passage growth factor-supplemented cultures showed a marked diminishment in the number of hepatocytes evident in control cultures ( Figure 1 IE), as compared to RAR treated cultures ( Figure 1 IF), indicative of a failure of growth factor supplementation alone to provide expanded and persistent hepatocytes in culture. Only RAR antagonist treatment enabled expansion and long-term culture of hepatocyte populations.
- LGN100754 was based on (i) Canan-Koch et al. J. Med. Chem. 39, 17, 3229-3234 [reaction scheme, page 3231; and (ii) Synthetic protocols from International Application No. PCT/US96/ 14876 (WO 97/12853) entitled Dimer-Selective RXR Modulators and Methods for Their Use. All materials were purchased from Ligand Pharmaceuticals Inc.
- Phosphorus oxychloride (0.234 grams, 0.142 ml, 1.52 mmol) was added dropwise to dimethyl formamide (DMF) (4 ml) at room temperature under a nitrogen atmosphere. The solution was sti ⁇ ed for 30 minutes. The l-(3-propoxy-5,6,7,8-tetrahydro-5,5,8,8,-tetramethylnaphthalen-2-yl) ethanone was added quickly (in one portion) to the orange solution, the reaction solution was heated to 60 °C and was sti ⁇ ed for 12 hours. The obtained dark brown solution was poured into ice water and the aqueous layer was adjusted to pH 7 with solid sodium hydrogen carbonate.
- DMF dimethyl formamide
- Ethyl magnesium bromide (3.33 ml of a 1.0 M solution in THF, 3.32 mmol) was added dropwise to a room temperature solution of the acetylene ether (6-ethynyl- 1 , 1 ,4,4,-tetramethyl-7-propoxy- 1 ,2 ,3 ,4-tetrahydronaphthalene) (0.450 grams, 1.66 mmol) in THF (10 ml). The solution was heated to reflux for 6 hours and then cooled to room temperature. Phenyl cyanate (0.40 grams, 0.50 ml, 3.33 mmol) was added (neat) to the reaction solution and the reflux was continued for additional 2 hours.
- the reaction mixture was warmed to 0 °C and sti ⁇ ed for 15 minutes.
- the resulting solution was then cooled to -78 °C and cis-3-(3-propoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-yl)but-2- enal (1.31 mmol) was added dropwise via cannula.
- the solution was warmed to ambient temperature. After stirring for 1.5 hours, the reaction was quenched with water (15 ml), and the aqueous layer was extracted with EtOAc (3 x 10 ml).
- Terephthalic acid monomethyl ester chloride (381 mg, 1.91 mmol) was added to a solution of 2-amino-l-methylamino-[l,2,3,4-tetrahydro- l,l,4,4-tetramethyl-naphthalene]benzene (420 mg, 1.3 mmol) in benzene (10 ml) and pyridine (2 ml). The mixture was sti ⁇ ed for 4 hours, then poured into 2N hydrochloric acid, and extracted with EtOAc.
- RXR, RAR and RAR+RXR antagonists supplementation of ex-vivo hematopoietic stem/progenitor cell cultures Cultures were prepared and maintained as described above. RXR, RAR, or RAR+RXR antagonists were added to some cultures at concentrations ranging from lO ⁇ M to 10 "9 M (100 ⁇ M to IO "3 M] concentrations co ⁇ esponding to diluting concentrations of 1550 ⁇ g/1 to 0.155 ⁇ g/l]. The antagonist was added for a predetermined, limited time period, for up to three weeks or continuously during the entire culture period.
- TPO cytokines
- FLT3, IL-6 and IL-3 cytokines
- HX-531 i.e., antagonist to both retinoic acid and retinoic X receptors
- RAR+RXR antagonist preferably enables marked proliferation, yet limited differentiation of the stem cell compartment, thus directly impact the high fold expansion of stem progenitor cells during short- and long-term culture period.
- Triphenylphosphine 99% (11.447 grams, 5.52 mmol) and DMSO were added to the reaction solution of methyl 4-iodo-2-methyl-butyrate described above and the resulting mixture was heated to 100 °C for 18 hours. The mixture was then cooled to -30 °C under nitrogen atmosphere, and the phenyl lithium solution in ether was added thereto.
- This reaction mixture was sti ⁇ ed at 0 °C for 1 hour and thereafter a hexane solution of the aldehyde CLP-8 Beta,5E,7E,20R,l ⁇ )- 1 ,3-bis-(tert-butyldimethylsilyloxy)-9, 10-secopregna-5,7, 1 0,(19)-triene-aldehyde - was added.
- the obtained mixture was sti ⁇ ed at 100 °C overnight.
- the ether and the hexane were thereafter distilled, the reaction mixture was cooled to 60 °C and 50 ml ethyl acetate in 75 ml water were added thereto.
- the obtained product was then treated with a solution of 15.2 mg iodine in 2 ml methylene chloride, in the presence of pyridine (12 mg) and the reaction mixture was evaporated under vacuum and thereafter under high vacuum. The residue was dissolved with THF and n-Bu 3 SnH (29.1 mg) was added thereto. The reaction mixture was sti ⁇ ed at room temperature for 4 hours and was thereafter evaporated under vacuum.
- Nicotinamide supplementation of ex-vivo hematopoietic stem/progenitor cell cultures Nicotinamide supplementation of ex-vivo hematopoietic stem/progenitor cell cultures:
- CD34+ cell cultures were initiated in the presence of a combination of 5 cytokines, SCF, TPO, FLt3, IL-6 and IL-3, with or without different concentrations of nicotinamide. Following three weeks incubation period, the CD34+ cells were re-selected from culture by affinity re-purification method and were enumerated. The results, presented in Figure 14, show that cultures supplemented with 1 and 5 mM nicotinamide yielded 99 x IO 4 and 180 x 10 CD34+ cells per ml, respectively, as compared with only 35 x IO 4 CD34+ cells per ml in the non-treated (cytokines only) control.
- the re-selected CD34+ cell fraction was FACS analyzed for stem progenitor cell markers.
- Figure 15 shows that cultures supplemented with 1 and 5 mM nicotinamide resulted in 1.7 and 51.7 fold increase, respectively, in CD34+/CD38- cells density, as compared with the untreated (cytokines only) control.
- Figure 16 shows that cultures supplemented with 1 and 5 mM nicotinamide resulted in 10.5 and 205.5 fold increase, respectively, in CD34+/Lin- cells density, as compared with the untreated (cytokines only) control.
- Figure 17 shows that cultures supplemented with 5 mM nicotinamide resulted in 11.5 fold increase in CD34+/(HLA-DR38-) cells density, as compared with the untreated (cytokines only) control.
- nicotinamide was found to be a very effective agent for promoting ex vivo expansion of stem and progenitor cells.
- 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992; 68: 397-406
- Drayson MT Michell RH, Durham J, Brown G. Cell proliferation and CDI lb expression are controlled independently during HL60 cell differentiation initiated by 1 ,25 alpha-dihydroxyvitamin D(3) or all-trans-retinoic acid. Exp Cell Res. 2001 ;266(1): 126-34 29. Gudas, LJ, Sporn, MB, & Roberts, AB. Cellular biology and biochemistry of the retinoids. In: The retinoids: biology, chemistry and medicine. 1994:443 516.
- Van Epps DE et al. Harvesting, characterization, and culture of CD34+ cells from human bone ma ⁇ ow, peripheral blood, and cord blood. Blood Cells 20:411, 1994.
- Emerson SG Ex-vivo expansion of hematopoietic precursors, progenitors, and stem cells: The next generation of cellular therapeutics. Blood 87:3082, 1996.
- Palmiter RD Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc Natl Acad Sci USA 91(4): 1219-1223, 1994.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
Abstract
Description
Claims
Priority Applications (30)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03706871A EP1576089B1 (en) | 2002-01-24 | 2003-01-26 | Expansion of renewable stem cell populations |
DE60332157T DE60332157D1 (en) | 2002-01-24 | 2003-01-26 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS |
CA2474344A CA2474344C (en) | 2002-01-24 | 2003-01-26 | Expansion of renewable stem cell populations |
JP2003562237A JP4738738B2 (en) | 2002-01-24 | 2003-01-26 | Expansion of renewable stem cell population |
AU2003208577A AU2003208577B9 (en) | 2002-01-24 | 2003-01-26 | Expansion of renewable stem cell populations |
AT03706871T ATE464372T1 (en) | 2002-01-24 | 2003-01-26 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS |
EP03710194A EP1485464A4 (en) | 2002-03-18 | 2003-03-18 | Methods of inducing differentiation in ex vivo expanded stem cells |
JP2003576562A JP2005520511A (en) | 2002-03-18 | 2003-03-18 | Methods for inducing differentiation in ex vivo expanded stem cells |
IL16399103A IL163991A0 (en) | 2002-03-18 | 2003-03-18 | Methods of inducing differentiation in ex vivo expanded stem cells |
AU2003214614A AU2003214614B2 (en) | 2002-03-18 | 2003-03-18 | Methods of inducing differentiation in ex vivo expanded stem cells |
US10/508,244 US20050220774A1 (en) | 2002-03-18 | 2003-03-18 | Methods of inducing differentiation in ex vivo expanded stem cells |
PCT/IL2003/000235 WO2003078567A2 (en) | 2002-03-18 | 2003-03-18 | Methods of inducing differentiation in ex vivo expanded stem cells |
CA002479679A CA2479679A1 (en) | 2002-03-18 | 2003-03-18 | Methods of inducing differentiation in ex vivo expanded stem cells |
BR0314402-0A BR0314402A (en) | 2002-08-19 | 2003-08-17 | Ex vivo expansion of root cell populations in mononuclear cell cultures |
CA002495824A CA2495824A1 (en) | 2002-08-19 | 2003-08-17 | Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
AU2003250519A AU2003250519A1 (en) | 2002-08-19 | 2003-08-17 | Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
MXPA05001992A MXPA05001992A (en) | 2002-08-19 | 2003-08-17 | Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures. |
JP2005502022A JP2006508692A (en) | 2002-08-19 | 2003-08-17 | Ex vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
EP03787995A EP1534820A4 (en) | 2002-08-19 | 2003-08-17 | Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
PCT/IL2003/000681 WO2004016731A2 (en) | 2002-08-19 | 2003-08-17 | Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
US10/774,843 US7955852B2 (en) | 2002-01-24 | 2004-02-09 | Expansion of renewable stem cell populations |
IL163180A IL163180A (en) | 2002-01-24 | 2004-07-22 | Expansion of renewable hematopoietic stem cell populations and use thereof |
AU2008229689A AU2008229689B9 (en) | 2002-01-24 | 2008-09-29 | Expansion of Renewable Stem Cell Populations |
AU2009200079A AU2009200079A1 (en) | 2002-03-18 | 2009-01-08 | Methods of inducing differentiation in ex vivo expanded stem cells |
US12/908,296 US20110033427A1 (en) | 2002-01-24 | 2010-10-20 | Expansion Of Renewable Stem Cell Populations |
AU2010241200A AU2010241200B2 (en) | 2002-01-24 | 2010-11-03 | Expansion of Renewable Stem Cell Populations |
IL229355A IL229355A0 (en) | 2002-01-24 | 2013-11-10 | Expansion of renewable stem cell populations |
US14/970,155 US20160097037A1 (en) | 2002-01-24 | 2015-12-15 | Expansion of renewable stem cell populations |
IL250313A IL250313B (en) | 2002-01-24 | 2017-01-26 | Expansion of renewable stem cell populations |
US16/036,638 US20180320139A1 (en) | 2002-01-24 | 2018-07-16 | Expansion of renewable stem cell populations |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35036002P | 2002-01-24 | 2002-01-24 | |
US60/350,360 | 2002-01-24 | ||
US37618302P | 2002-04-30 | 2002-04-30 | |
US60/376,183 | 2002-04-30 | ||
US40413702P | 2002-08-19 | 2002-08-19 | |
US60/404,137 | 2002-08-19 | ||
IL15290402A IL152904A0 (en) | 2002-01-24 | 2002-11-17 | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
IL152904 | 2002-11-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/774,843 Continuation US7955852B2 (en) | 2002-01-24 | 2004-02-09 | Expansion of renewable stem cell populations |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003062369A2 true WO2003062369A2 (en) | 2003-07-31 |
WO2003062369A3 WO2003062369A3 (en) | 2006-03-30 |
Family
ID=27617675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2003/000064 WO2003062369A2 (en) | 2002-01-24 | 2003-01-26 | Expansion of renewable stem cell populations |
Country Status (11)
Country | Link |
---|---|
US (2) | US7955852B2 (en) |
EP (3) | EP1576089B1 (en) |
JP (2) | JP4738738B2 (en) |
AT (1) | ATE464372T1 (en) |
AU (3) | AU2003208577B9 (en) |
CA (1) | CA2474344C (en) |
DE (1) | DE60332157D1 (en) |
ES (2) | ES2391318T3 (en) |
HK (1) | HK1146091A1 (en) |
IL (4) | IL152904A0 (en) |
WO (1) | WO2003062369A2 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1648397A2 (en) * | 2003-07-17 | 2006-04-26 | Gamida Cell Ltd. | Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs |
EP1649007A2 (en) * | 2003-07-17 | 2006-04-26 | Gamida Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
WO2007136653A2 (en) * | 2006-05-16 | 2007-11-29 | Vitae Pharmaceuticals, Inc. | Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
WO2008014430A1 (en) | 2006-07-27 | 2008-01-31 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
AU2005200679B2 (en) * | 2002-08-19 | 2008-11-20 | Gamida-Cell Ltd. | Ex-Vivo Expansion of Hematopoietic Stem Cell Populations in Mononuclear Cell Cultures |
US7655225B2 (en) | 2002-01-25 | 2010-02-02 | Gamida Cell, Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
US7855075B2 (en) | 1998-02-17 | 2010-12-21 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US7955852B2 (en) | 2002-01-24 | 2011-06-07 | Gamida Cell Ltd. | Expansion of renewable stem cell populations |
WO2011080740A1 (en) | 2009-12-29 | 2011-07-07 | Gamida-Cell Ltd. | Methods for enhancing natural killer cell proliferation and activity |
US20110172185A1 (en) * | 2008-09-22 | 2011-07-14 | Masanori Baba | Therapeutic drug for adult t-cell leukemia |
US8080417B2 (en) * | 2004-09-16 | 2011-12-20 | Gamida-Cell Ltd. | Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells |
US8187876B2 (en) * | 2004-07-14 | 2012-05-29 | Gamida Cell Ltd. | Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the Sir2 family of enzymes |
WO2013121426A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9308186B2 (en) | 2005-09-30 | 2016-04-12 | Io Therapeutics, Inc. | Treatment of cancer with specific RXR agonists |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
WO2017152725A1 (en) * | 2016-03-11 | 2017-09-14 | 中国科学院上海有机化学研究所 | Retinoid compound, preparation method therefor, intermediates thereof and application thereof |
CN107176945A (en) * | 2016-03-11 | 2017-09-19 | 中国科学院上海有机化学研究所 | A kind of retinoid compound, its preparation method, intermediate and application |
EP3452581A4 (en) * | 2016-05-03 | 2019-12-04 | University Health Network | 4hpr and its use in the culturing of hematopoietic stem cells |
US10588881B2 (en) | 2015-10-31 | 2020-03-17 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10835507B2 (en) | 2016-03-10 | 2020-11-17 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
EP3573627A4 (en) * | 2017-01-24 | 2020-11-25 | Fred Hutchinson Cancer Research Center | Systems and methods for hematopoietic cell expansion utilizing hydrogels |
US10945976B2 (en) | 2011-12-13 | 2021-03-16 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US10946001B2 (en) | 2016-03-10 | 2021-03-16 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
US11517549B2 (en) | 2017-09-20 | 2022-12-06 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US11802269B2 (en) | 2016-09-30 | 2023-10-31 | Poseida Therapeutics, Inc. | Superpiggybac transposase compositions |
US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
US11998521B2 (en) | 2021-12-07 | 2024-06-04 | Io Therapeutics, Inc. | Use of an RXR agonist in treating drug resistant HER2+ cancers |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007528226A (en) * | 2004-03-10 | 2007-10-11 | リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | Composition and method for propagation of embryonic stem cells |
WO2005113749A2 (en) | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Stem cell populations and methods of use |
US20070003528A1 (en) | 2005-06-29 | 2007-01-04 | Paul Consigny | Intracoronary device and method of use thereof |
WO2007033331A2 (en) * | 2005-09-14 | 2007-03-22 | Duke University | Stem cells |
WO2007063545A2 (en) * | 2005-11-29 | 2007-06-07 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
JP5646990B2 (en) | 2007-04-23 | 2014-12-24 | ストワーズ インスティテュート フォー メディカル リサーチ | Methods and compositions for stem cell self-renewal |
US8574567B2 (en) | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
EP2155860B1 (en) | 2007-05-03 | 2014-08-27 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
KR101506751B1 (en) | 2007-05-17 | 2015-03-27 | 디나벡크 가부시키가이샤 | Method for production of dendritic cell |
US8082730B2 (en) * | 2008-05-20 | 2011-12-27 | Caterpillar Inc. | Engine system having particulate reduction device and method |
IT1391663B1 (en) * | 2008-11-10 | 2012-01-17 | Giuliani Spa | USE OF COMPOUNDS TO INHIBIT THE ACTIVITY OF THE ENZYME 5ALPHE-REDUCTASE AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT CONTAIN THEM |
US9056085B2 (en) * | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
US9051548B2 (en) | 2009-02-03 | 2015-06-09 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
WO2010128510A1 (en) * | 2009-05-07 | 2010-11-11 | Gamida-Cell Ltd. | Methods for selecting expanded stem cell populations |
WO2012048275A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
JP2014506453A (en) * | 2011-01-19 | 2014-03-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Innate pluripotent somatic cells |
UA117448C2 (en) * | 2011-06-29 | 2018-08-10 | Зе Дженерел Хоспітел Корпорейшн | Compositions and methods for enhancing bioenergetic status in female germ cells |
WO2013184193A2 (en) * | 2012-06-04 | 2013-12-12 | Medimmune, Llc | Cancer stem cells and methods of using the same |
CA2927712A1 (en) | 2013-10-24 | 2015-04-30 | Ospedale San Raffaele S.R.L. | Method for the genetic modification of haematopoietic stem and progenitor cells (hspcs) and the use of genetically modified hspcs in gene therapy |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
US9594947B1 (en) * | 2014-09-30 | 2017-03-14 | Amazon Technologies, Inc. | Aspect ratio validation |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
EP3519561A1 (en) * | 2016-09-30 | 2019-08-07 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656842A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
CA3063674A1 (en) | 2017-05-16 | 2018-11-22 | Gamida-Cell Ltd. | Selection and use of umbilical cord cell fractions suitable for transplantation |
US11746325B2 (en) | 2017-05-16 | 2023-09-05 | Gamida Cell Ltd. | Selection and use of umbilical cord cell fractions suitable for transplantation |
JP2024511064A (en) | 2021-03-23 | 2024-03-12 | テルモ ビーシーティー、インコーポレーテッド | Cell capture and proliferation |
CN113583940A (en) * | 2021-08-31 | 2021-11-02 | 成都以邦医药科技有限公司 | Liver oval cell immortalized culture medium and preparation method and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5545807A (en) | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5569825A (en) | 1990-08-29 | 1996-10-29 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1997012853A1 (en) | 1995-10-06 | 1997-04-10 | Ligand Pharmaceuticals Incorporated | Dimer-selective rxr modulators and methods for their use |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6303374B1 (en) | 2000-01-18 | 2001-10-16 | Isis Pharmaceuticals Inc. | Antisense modulation of caspase 3 expression |
Family Cites Families (200)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US687808A (en) | 1901-06-11 | 1901-12-03 | Louis W Witry | Friction-clutch. |
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
US3715345A (en) * | 1970-08-03 | 1973-02-06 | Lilly Co Eli | Glucagon separation process |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3936074A (en) * | 1971-12-16 | 1976-02-03 | Ernesto Prinoth | Vehicle chassis |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3876623A (en) * | 1973-05-09 | 1975-04-08 | Lilly Co Eli | Process for purifying insulin |
US3863008A (en) * | 1973-06-11 | 1975-01-28 | American Home Prod | Somatostatin as stimulant of luteinizing hormone secretion |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
US4687808A (en) | 1982-08-12 | 1987-08-18 | Biospecific Technologies, Inc. | Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors |
IL68218A (en) | 1983-03-23 | 1985-12-31 | Univ Ramot | Compositions for cartilage repair comprising embryonal chondrocytes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4584284A (en) | 1985-01-31 | 1986-04-22 | Ortho Pharmaceutical Corporation | Bursopoietin |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
GB8606913D0 (en) * | 1986-03-20 | 1986-04-23 | Hider R C | Treatment of sickle cell disease |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4806484A (en) * | 1987-08-07 | 1989-02-21 | Igb Products, Ltd. | Perfusion airlift bioreactor |
WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
EP0348458B1 (en) | 1987-11-30 | 1997-04-09 | University Of Iowa Research Foundation | Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
ATE110108T1 (en) | 1987-12-11 | 1994-09-15 | Whitehead Biomedical Inst | GENETIC MODIFICATION OF ENDOTHELIAL CELLS. |
JP2917998B2 (en) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | Modified hepatocytes and their uses |
JPH01222780A (en) | 1988-03-02 | 1989-09-06 | Tosoh Corp | Method for refolding urokinase precursor-like protein |
JPH03503894A (en) | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | Oligonucleotide N-alkylphosphoramidate |
US5081035A (en) * | 1988-04-18 | 1992-01-14 | The University Of Michigan | Bioreactor system |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5437994A (en) * | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5612211A (en) * | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US6326198B1 (en) | 1990-06-14 | 2001-12-04 | Regents Of The University Of Michigan | Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
HU217036B (en) | 1990-08-03 | 1999-11-29 | Sanofi | Methods for making of compounds which can inhibit the gene expression |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
CA2092002A1 (en) | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
AU659824B2 (en) | 1990-10-31 | 1995-06-01 | Cell Genesys, Inc. | Retroviral vectors useful for gene therapy |
US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US5811094A (en) * | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5837539A (en) * | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US5320963A (en) * | 1992-11-25 | 1994-06-14 | National Research Council Of Canada | Bioreactor for the perfusion culture of cells |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
WO1994022891A1 (en) | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
US5342781A (en) * | 1993-07-15 | 1994-08-30 | Su Wei Wen W | External-loop perfusion air-lift bioreactor |
US5378725A (en) * | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
AU7515294A (en) | 1993-07-28 | 1995-02-28 | Fred Hutchinson Cancer Research Center | Creating novel hematopoietic cell lines by expressing altered retinoic acid receptors |
US5504103A (en) * | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5789543A (en) * | 1993-12-30 | 1998-08-04 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins and uses related thereto |
ATE196311T1 (en) | 1993-12-09 | 2000-09-15 | Univ Jefferson | COMPOUNDS AND METHODS FOR SITE-SPECIFIC MUTATION IN EUKARYOTIC CELLS |
US6271363B1 (en) * | 1993-12-30 | 2001-08-07 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
US6165747A (en) | 1993-12-30 | 2000-12-26 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
US6261786B1 (en) * | 1993-12-30 | 2001-07-17 | Imperial Cancer Res. Technology | Screening assays for hedgehog agonists and antagonists |
US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5489304A (en) | 1994-04-19 | 1996-02-06 | Brigham & Women's Hospital | Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft |
US5480906A (en) * | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
US5770378A (en) * | 1994-12-30 | 1998-06-23 | Ligand Pharmaceuticals, Inc. | Tricyclic retinoids, methods for their production and use |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5741899A (en) * | 1995-02-02 | 1998-04-21 | Cell Genesys, Inc. | Chimeric receptors comprising janus kinase for regulating cellular pro liferation |
US5716616A (en) | 1995-03-28 | 1998-02-10 | Thomas Jefferson University | Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects |
US5674750A (en) * | 1995-05-19 | 1997-10-07 | T. Breeders | Continuous selective clonogenic expansion of relatively undifferentiated cells |
US5925567A (en) * | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
US6680166B1 (en) * | 1995-06-07 | 2004-01-20 | Claudy Jean Paul Mullon | Dual fiber bioreactor |
US5712154A (en) * | 1995-06-07 | 1998-01-27 | W.R. Grace & Co.-Conn. | Dual fiber bioreactor |
US6306575B1 (en) | 1995-06-16 | 2001-10-23 | Stemcell Technologies, Inc. | Methods for preparing enriched human hematopoietic cell preparations |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US6117850A (en) * | 1995-08-28 | 2000-09-12 | The Collaborative Group, Ltd. | Mobilization of peripheral blood precursor cells by β(1,3)-glucan |
US6218128B1 (en) * | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US5958954A (en) * | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5952345A (en) * | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
US6008204A (en) * | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6329169B1 (en) | 1995-09-29 | 2001-12-11 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding cytostatin II |
FR2739777B1 (en) * | 1995-10-11 | 1997-11-14 | Cird Galderma | LIGAND ANTAGONIST RAR-GAMMA OR AGONIST RAR-ALPHA AS AN APOPTOSIS INHIBITOR |
US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
CA2248142A1 (en) * | 1996-03-12 | 1997-09-18 | Life Technologies, Inc. | Hematopoietic cell culture nutrient supplement |
US6043092A (en) * | 1996-03-18 | 2000-03-28 | University Of Pittsburgh | Cell culture media for mammalian cells |
US5945309A (en) * | 1996-03-19 | 1999-08-31 | Human Genome Sciences, Inc. | Cytostatin III nucleic acids encoding |
TW442459B (en) | 1996-04-15 | 2001-06-23 | Hoffmann La Roche | Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof |
US6190910B1 (en) | 1996-05-21 | 2001-02-20 | The Institute Of Physical And Chemical Research | Mouse embryonic stem cell lines |
US5851984A (en) | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
CA2263817A1 (en) * | 1996-08-28 | 1998-03-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Therapeutic combinations of rar antagonists and rxr agonists and use thereof |
US5945337A (en) * | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
US6335195B1 (en) * | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
CA2196496A1 (en) * | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US6294330B1 (en) * | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
US20030215445A1 (en) | 1997-05-23 | 2003-11-20 | Ginette Serrero | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
US6372473B1 (en) * | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
JP3014343B2 (en) * | 1997-06-06 | 2000-02-28 | 科学技術振興事業団 | Hepatocyte culture method |
JP2002513295A (en) * | 1997-07-08 | 2002-05-08 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 123 human secreted proteins |
US6440734B1 (en) | 1998-09-25 | 2002-08-27 | Cytomatrix, Llc | Methods and devices for the long-term culture of hematopoietic progenitor cells |
ZA9810122B (en) * | 1997-11-12 | 1999-05-12 | Hoffmann La Roche | Treatment of T-helper cell type 2 mediated immune diseases |
US6962698B1 (en) * | 1998-02-17 | 2005-11-08 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
IL137757A0 (en) | 1998-02-17 | 2001-10-31 | Gamida Cell Ltd | Method of controlling proliferation and differentiation of stem and progenitor cells |
US6886568B2 (en) * | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
US6413773B1 (en) * | 1998-06-01 | 2002-07-02 | The Regents Of The University Of California | Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation |
JP2003523166A (en) | 1998-09-29 | 2003-08-05 | ガミダ セル リミテッド | Methods for controlling proliferation and differentiation of stem and progenitor cells |
US20020002269A1 (en) * | 1998-09-29 | 2002-01-03 | Jeffrey D. Milbrandt | Artemin, a neurotrophic factor |
CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
JP4926320B2 (en) * | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Compositions and methods for cancer treatment by selective inhibition of VEGF |
US7456017B2 (en) * | 1999-10-01 | 2008-11-25 | University Of North Carolina At Chapel Hill | Processes for clonal growth of hepatic progenitor cells |
US6541249B2 (en) * | 1999-12-22 | 2003-04-01 | Human Genome Sciences, Inc. | Immortalized human stromal cell lines |
WO2001094549A2 (en) * | 2000-06-05 | 2001-12-13 | The Burnham Institute | Methods of differentiating and protecting cells by modulating the p38/mef2 pathway |
JP2004504834A (en) | 2000-08-01 | 2004-02-19 | イスム リサーチ ディベロップメント カンパニー | Directed differentiation of embryonic cells |
AU2000277535B2 (en) * | 2000-10-03 | 2007-03-29 | University Of North Carolina At Chapel Hill | Processes for clonal growth of hepatic progenitor cells |
US7198940B2 (en) | 2000-10-25 | 2007-04-03 | Shot Hardware Optimization Technology, Inc. | Bioreactor apparatus and cell culturing system |
ES2171131B1 (en) | 2000-11-10 | 2003-12-16 | Idebio S L | QUITOSANE BASED BIOLOGICAL PESTICIDE |
US6642019B1 (en) | 2000-11-22 | 2003-11-04 | Synthecan, Inc. | Vessel, preferably spherical or oblate spherical for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using same |
DE10103402B4 (en) | 2001-01-26 | 2005-11-24 | Daimlerchrysler Ag | Exterior rearview mirror of a motor vehicle |
EP1385935A4 (en) | 2001-03-29 | 2004-09-15 | Ixion Biotechnology Inc | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway |
JP2004533449A (en) * | 2001-05-11 | 2004-11-04 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | Anti-CD26 monoclonal antibodies for the treatment of diseases associated with cells expressing CD26 |
DE10131388B4 (en) * | 2001-06-28 | 2004-07-08 | Infineon Technologies Ag | Integrated dynamic memory and method for operating the same |
WO2003035618A2 (en) * | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
US6887401B2 (en) * | 2001-11-05 | 2005-05-03 | Essilor International Compagnie General D'optique | Method for making transparent polythiourethane substrates in particular optical substrates |
AUPR892501A0 (en) | 2001-11-16 | 2001-12-13 | Peter Maccallum Cancer Institute, The | Method of enhancing self renewal of stem cells and uses thereof |
US7514075B2 (en) * | 2001-12-07 | 2009-04-07 | Cytori Therapeutics, Inc. | Systems and methods for separating and concentrating adipose derived stem cells from tissue |
US20050095228A1 (en) * | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
EP1485464A4 (en) | 2002-03-18 | 2006-11-29 | Gamida Cell Ltd | Methods of inducing differentiation in ex vivo expanded stem cells |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7247477B2 (en) * | 2002-04-16 | 2007-07-24 | Technion Research & Development Foundation Ltd. | Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells |
JP2006508692A (en) * | 2002-08-19 | 2006-03-16 | ガミダ セル リミテッド | Ex vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
US7470538B2 (en) * | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
EP1601759A4 (en) * | 2003-03-07 | 2007-02-14 | Gamida Cell Ltd | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
US20040247574A1 (en) | 2003-05-27 | 2004-12-09 | Christopherson Kent W. | Methods for enhancing stem cell engraftment during transplantation |
WO2005007799A2 (en) * | 2003-07-17 | 2005-01-27 | Gamida-Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
JP2007528226A (en) * | 2004-03-10 | 2007-10-11 | リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | Composition and method for propagation of embryonic stem cells |
WO2006030442A2 (en) * | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
RU2007132733A (en) * | 2005-01-31 | 2009-03-10 | Когнейт Терапьютикс, Инк. (Us) | STOMAL CELLS SEPARATED FROM FAT TISSUE OF AN ADULT ORGANISM MANIFESTING PROPERTIES OF ENDOTHELIAL CELLS |
-
2002
- 2002-11-17 IL IL15290402A patent/IL152904A0/en unknown
-
2003
- 2003-01-26 AU AU2003208577A patent/AU2003208577B9/en not_active Expired
- 2003-01-26 WO PCT/IL2003/000064 patent/WO2003062369A2/en active Application Filing
- 2003-01-26 ES ES10003540T patent/ES2391318T3/en not_active Expired - Lifetime
- 2003-01-26 EP EP03706871A patent/EP1576089B1/en not_active Expired - Lifetime
- 2003-01-26 AT AT03706871T patent/ATE464372T1/en not_active IP Right Cessation
- 2003-01-26 DE DE60332157T patent/DE60332157D1/en not_active Expired - Lifetime
- 2003-01-26 ES ES03706871T patent/ES2344258T3/en not_active Expired - Lifetime
- 2003-01-26 JP JP2003562237A patent/JP4738738B2/en not_active Expired - Lifetime
- 2003-01-26 EP EP10003540A patent/EP2206773B1/en not_active Expired - Lifetime
- 2003-01-26 CA CA2474344A patent/CA2474344C/en not_active Expired - Lifetime
- 2003-01-26 EP EP10010858A patent/EP2305794A1/en not_active Withdrawn
-
2004
- 2004-02-09 US US10/774,843 patent/US7955852B2/en active Active
- 2004-07-22 IL IL163180A patent/IL163180A/en active IP Right Grant
-
2008
- 2008-09-29 AU AU2008229689A patent/AU2008229689B9/en not_active Expired
-
2010
- 2010-10-20 US US12/908,296 patent/US20110033427A1/en not_active Abandoned
- 2010-11-03 AU AU2010241200A patent/AU2010241200B2/en not_active Expired
-
2011
- 2011-01-13 HK HK11100299.5A patent/HK1146091A1/en not_active IP Right Cessation
- 2011-03-02 JP JP2011045102A patent/JP2011155976A/en active Pending
-
2013
- 2013-11-10 IL IL229355A patent/IL229355A0/en unknown
-
2017
- 2017-01-26 IL IL250313A patent/IL250313B/en active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5545807A (en) | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5569825A (en) | 1990-08-29 | 1996-10-29 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1997012853A1 (en) | 1995-10-06 | 1997-04-10 | Ligand Pharmaceuticals Incorporated | Dimer-selective rxr modulators and methods for their use |
US6303374B1 (en) | 2000-01-18 | 2001-10-16 | Isis Pharmaceuticals Inc. | Antisense modulation of caspase 3 expression |
Non-Patent Citations (31)
Title |
---|
"Advanced in Pharmacology", vol. 40, 1997, ACADEMIC PRESS, article "Gene Therapy" |
"This embodiment of the present invention is of particular", STEM CELLS, vol. 18, 2000, pages 295 |
ANTHONY D. HO (EDITOR) RICHARD CHAMPLIN (EDITOR): "Hematopoietic Stem Cell Transplantation", 2000, MARCEL DEKKER |
BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95 |
BOHMER RM, FETAL DIAGN THER, vol. 17, 2002, pages 83 |
CANAN-KOCH ET AL., J. MED. CHEM., vol. 39, no. 17, pages 3229 - 3234 |
COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, pages: 77 |
DANIEL R. MARSHAK (EDITOR) RICHARD L. GARDNER (EDITOR): "Stem Cell Biology", 2001, COLD SPRING HARBOR LABORATORY PRESS |
ENGLISCH ET AL., ANGEWANDTE CHEMIE, vol. 30, 1991, pages 613 |
FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 51 |
HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1991, pages 381 |
KROSCHWITZ, J. I.,: "The Concise Encyclopedia Of Polymer Science And Engineering", 1990, JOHN WILEY & SONS, pages: 858 - 859 |
LEE ET AL., BIOL. CHEM., vol. 380, 1999, pages 785 - 793 |
LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859 |
LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93 |
MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783 |
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 |
MIRAGLIA, S. ET AL., BLOOD, vol. 90, 1997, pages 5013 |
MORRISON, NATURE, vol. 368, 1994, pages 812 - 13 |
MUNSHI CB; GRAEFF R; LEE HC, J BIOL CHEM, vol. 277, no. 51, 20 December 2002 (2002-12-20), pages 49453 - 8 |
NEUBERGER, NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 826 |
PODESTA, FASEB J., vol. 14, 2000, pages 680 - 690 |
PROCKOP DJ, CYTOTHERAPY, vol. 3, 2001, pages 393 |
ROACH ML, METHODS MOL BIOL, vol. 185, 2002, pages 1 |
ROWLEY SD ET AL., BONE MARROW TRANSPLANT, vol. 21, 1998, pages 1253 |
SANGHVI YS ET AL.: "Antisense Research and Applications", 1993, CRC PRESS, pages: 276 - 278 |
SANGHVI, Y. S.: "Antisense Research and Applications", 1993, CRC PRESS, article "Chapter 15,", pages: 289 - 302 |
SIMMONS, P.J. ET AL., BLOOD, vol. 78, 1991, pages 55 |
SMITH AG, ANNU REV CELL DEV BIOL, vol. 17, 2001, pages 435 |
TROUNSON AO, REPROD FERTIL DEV, vol. 13, 2001, pages 523 |
UCHIDA, N. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 14720 |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7855075B2 (en) | 1998-02-17 | 2010-12-21 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US7955852B2 (en) | 2002-01-24 | 2011-06-07 | Gamida Cell Ltd. | Expansion of renewable stem cell populations |
US7655225B2 (en) | 2002-01-25 | 2010-02-02 | Gamida Cell, Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
AU2005200679B2 (en) * | 2002-08-19 | 2008-11-20 | Gamida-Cell Ltd. | Ex-Vivo Expansion of Hematopoietic Stem Cell Populations in Mononuclear Cell Cultures |
EP1649007A2 (en) * | 2003-07-17 | 2006-04-26 | Gamida Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
EP1648397A2 (en) * | 2003-07-17 | 2006-04-26 | Gamida Cell Ltd. | Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs |
EP1649007A4 (en) * | 2003-07-17 | 2008-05-14 | Gamida Cell Ltd | Methods for ex-vivo expanding stem/progenitor cells |
EP1648397A4 (en) * | 2003-07-17 | 2008-05-21 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs |
US8986992B2 (en) | 2004-07-14 | 2015-03-24 | Gamida Cell Ltd. | Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the Sir2 family of enzymes |
US8187876B2 (en) * | 2004-07-14 | 2012-05-29 | Gamida Cell Ltd. | Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the Sir2 family of enzymes |
US8080417B2 (en) * | 2004-09-16 | 2011-12-20 | Gamida-Cell Ltd. | Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells |
US9655872B2 (en) | 2005-09-30 | 2017-05-23 | Io Therapeutics, Inc. | Treatment of cancer with specific RXR agonists |
US10039731B2 (en) | 2005-09-30 | 2018-08-07 | Io Therapeutics, Inc. | Treatment of cancer with specific RXR agonists |
US10973788B2 (en) | 2005-09-30 | 2021-04-13 | Io Therapeutics, Inc. | Treatment of cancer with specific RXR agonists |
US9717702B2 (en) | 2005-09-30 | 2017-08-01 | Io Therapeutics, Inc. | Treatment of cancer with specific RXR agonists |
US10596133B2 (en) | 2005-09-30 | 2020-03-24 | Io Therapeutics, Inc. | Treatment of cancer with specific RXR agonists |
US10188618B2 (en) | 2005-09-30 | 2019-01-29 | Io Therapeutics, Inc. | Treatment of cancer with specific RXR agonists |
US9308186B2 (en) | 2005-09-30 | 2016-04-12 | Io Therapeutics, Inc. | Treatment of cancer with specific RXR agonists |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
WO2007136653A2 (en) * | 2006-05-16 | 2007-11-29 | Vitae Pharmaceuticals, Inc. | Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
US9271946B2 (en) | 2006-05-16 | 2016-03-01 | Io Therapeutics, Inc. | Use of a RAR antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
WO2007136653A3 (en) * | 2006-05-16 | 2008-07-03 | Vitae Pharmaceuticals Inc | Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
US9873667B2 (en) | 2006-07-27 | 2018-01-23 | Emisphere Technologies Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
WO2008014430A1 (en) | 2006-07-27 | 2008-01-31 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
EP2046736A1 (en) * | 2006-07-27 | 2009-04-15 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
EP2046736A4 (en) * | 2006-07-27 | 2011-07-13 | Emisphere Tech Inc | Arylsulfanyl compounds and compositions for delivering active agents |
US8765719B2 (en) * | 2008-09-22 | 2014-07-01 | Kagoshima University | Therapeutic drug for adult T-cell leukemia |
JP5516894B2 (en) * | 2008-09-22 | 2014-06-11 | 国立大学法人 鹿児島大学 | Adult T-cell leukemia drug |
US20110172185A1 (en) * | 2008-09-22 | 2011-07-14 | Masanori Baba | Therapeutic drug for adult t-cell leukemia |
EP3785712A1 (en) | 2009-12-29 | 2021-03-03 | Gamida-Cell Ltd. | Methods for enhancing natural killer cell proliferation and activity |
WO2011080740A1 (en) | 2009-12-29 | 2011-07-07 | Gamida-Cell Ltd. | Methods for enhancing natural killer cell proliferation and activity |
EP3184109A1 (en) | 2009-12-29 | 2017-06-28 | Gamida-Cell Ltd. | Methods for enhancing natural killer cell proliferation and activity |
US11793781B2 (en) | 2011-12-13 | 2023-10-24 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11166927B2 (en) | 2011-12-13 | 2021-11-09 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11246845B2 (en) | 2011-12-13 | 2022-02-15 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11547684B2 (en) | 2011-12-13 | 2023-01-10 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US10945976B2 (en) | 2011-12-13 | 2021-03-16 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11576881B2 (en) | 2011-12-13 | 2023-02-14 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
WO2013121426A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
WO2013121427A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Mesenchymal stem cells conditioned medium and methods of generating and using the same |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US10980759B2 (en) | 2015-10-31 | 2021-04-20 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10588881B2 (en) | 2015-10-31 | 2020-03-17 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10695312B2 (en) | 2015-10-31 | 2020-06-30 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10857117B2 (en) | 2015-10-31 | 2020-12-08 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US11065219B2 (en) | 2015-10-31 | 2021-07-20 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10842764B2 (en) | 2015-10-31 | 2020-11-24 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10980761B2 (en) | 2015-10-31 | 2021-04-20 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10702489B2 (en) | 2015-10-31 | 2020-07-07 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10980760B2 (en) | 2015-10-31 | 2021-04-20 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10973791B2 (en) | 2015-10-31 | 2021-04-13 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10806713B2 (en) | 2015-10-31 | 2020-10-20 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10835507B2 (en) | 2016-03-10 | 2020-11-17 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
US10946001B2 (en) | 2016-03-10 | 2021-03-16 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
US11690831B2 (en) | 2016-03-10 | 2023-07-04 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
US11690832B2 (en) | 2016-03-10 | 2023-07-04 | Io Therapeutics | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
CN107176945B (en) * | 2016-03-11 | 2021-06-08 | 中国科学院上海有机化学研究所 | Retinoid compound, preparation method, intermediate and application thereof |
WO2017152725A1 (en) * | 2016-03-11 | 2017-09-14 | 中国科学院上海有机化学研究所 | Retinoid compound, preparation method therefor, intermediates thereof and application thereof |
CN107176945A (en) * | 2016-03-11 | 2017-09-19 | 中国科学院上海有机化学研究所 | A kind of retinoid compound, its preparation method, intermediate and application |
US10556879B2 (en) | 2016-03-11 | 2020-02-11 | Shanghai Institute Of Organic Chemistry, Chinese Acadmeny Of Sciences | Retinoid compound, preparation method therefor, intermediates thereof and application thereof |
EP3452581A4 (en) * | 2016-05-03 | 2019-12-04 | University Health Network | 4hpr and its use in the culturing of hematopoietic stem cells |
US11802269B2 (en) | 2016-09-30 | 2023-10-31 | Poseida Therapeutics, Inc. | Superpiggybac transposase compositions |
EP3573627A4 (en) * | 2017-01-24 | 2020-11-25 | Fred Hutchinson Cancer Research Center | Systems and methods for hematopoietic cell expansion utilizing hydrogels |
US11517549B2 (en) | 2017-09-20 | 2022-12-06 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US11224583B2 (en) | 2019-06-11 | 2022-01-18 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
US11998521B2 (en) | 2021-12-07 | 2024-06-04 | Io Therapeutics, Inc. | Use of an RXR agonist in treating drug resistant HER2+ cancers |
Also Published As
Publication number | Publication date |
---|---|
EP1576089B1 (en) | 2010-04-14 |
CA2474344C (en) | 2013-10-22 |
EP2305794A1 (en) | 2011-04-06 |
AU2003208577B2 (en) | 2008-07-10 |
EP1576089A2 (en) | 2005-09-21 |
ES2344258T3 (en) | 2010-08-23 |
US20110033427A1 (en) | 2011-02-10 |
ES2391318T3 (en) | 2012-11-23 |
AU2008229689B9 (en) | 2011-07-28 |
AU2008229689A1 (en) | 2008-10-30 |
JP2005528088A (en) | 2005-09-22 |
AU2010241200B2 (en) | 2012-02-16 |
IL250313A0 (en) | 2017-03-30 |
IL152904A0 (en) | 2003-06-24 |
ATE464372T1 (en) | 2010-04-15 |
US7955852B2 (en) | 2011-06-07 |
AU2003208577B9 (en) | 2008-07-31 |
WO2003062369A3 (en) | 2006-03-30 |
US20050008624A1 (en) | 2005-01-13 |
IL163180A (en) | 2014-08-31 |
JP4738738B2 (en) | 2011-08-03 |
EP2206773B1 (en) | 2012-07-11 |
AU2010241200A1 (en) | 2010-11-25 |
DE60332157D1 (en) | 2010-05-27 |
JP2011155976A (en) | 2011-08-18 |
HK1146091A1 (en) | 2011-05-13 |
IL229355A0 (en) | 2013-12-31 |
CA2474344A1 (en) | 2003-07-31 |
AU2008229689B2 (en) | 2011-04-07 |
IL250313B (en) | 2019-06-30 |
EP1576089A4 (en) | 2007-02-14 |
EP2206773A1 (en) | 2010-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2206773B1 (en) | Expansion of renewable stem cell populations | |
AU2004217699B2 (en) | Expansion of renewable stem cell populations using modulators of PI 3-kinase | |
AU2003208577A1 (en) | Expansion of renewable stem cell populations | |
US20070077652A1 (en) | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells | |
Dolznig et al. | Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR | |
WO2006006171A2 (en) | Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the sir2 family of enzymes | |
US20050054097A1 (en) | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures | |
CA2495824A1 (en) | Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures | |
US20180320139A1 (en) | Expansion of renewable stem cell populations | |
ZA200405901B (en) | Expansion of renewable stem cell populations | |
AU2005200679B2 (en) | Ex-Vivo Expansion of Hematopoietic Stem Cell Populations in Mononuclear Cell Cultures | |
Di Bella | The PERK (s) of having your own niche: how Acute Myeloid Leukaemia transforms the Bone Marrow Microenvironment | |
ZA200502111B (en) | Ex-vivo expansion of hematopoietic stem cell popu lations in mononuclear cell cultures. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10774843 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163180 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/05901 Country of ref document: ZA Ref document number: 200405901 Country of ref document: ZA Ref document number: 2003562237 Country of ref document: JP Ref document number: 2474344 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003208577 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003706871 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003706871 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 206753 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 250313 Country of ref document: IL |